Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
CYP2C9 1559 TAMOXIFEN CHEMBL83 PharmGKB
CYP2C9 1559 CYCLOPHOSPHAMIDE CHEMBL88 PharmGKB
CYP2C9 1559 GLIPIZIDE CHEMBL1073 PharmGKB
CYP2C9 1559 IRBESARTAN CHEMBL1513 PharmGKB
CYP2C9 1559 CELECOXIB CHEMBL118 FDA
CYP2C9 1559 Para-Hydroxymercuribenzoic acid CHEMBL78771 inhibitor GuideToPharmacologyInteractions
CYP2C9 1559 FLIBANSERIN CHEMBL231068 FDA
CYP2C9 1559 DIAZEPAM CHEMBL12 PharmGKB
CYP2C9 1559 FLURBIPROFEN CHEMBL563 FDA
CYP2C9 1559 MELOXICAM CHEMBL599 PharmGKB
CYP2C9 1559 PIROXICAM CHEMBL527 PharmGKB, FDA
CYP2C9 1559 DRONABINOL CHEMBL465 FDA
CYP2C9 1559 LESINURAD CHEMBL2105720 FDA
CYP2C9 1559 CHEMBL251074 CHEMBL251074 DrugBank 10592235
CYP2C9 1559 PHENYTOIN CHEMBL16 FDA
CYP2C9 1559 PRASUGREL CHEMBL1201772 FDA
CYP2C9 1559 WARFARIN CHEMBL1464 NCI, FDA 15050794
CYP2C9 1559 CAFFEINE CHEMBL113 PharmGKB
CYP2C9 1559 NAPROXEN CHEMBL154 PharmGKB, NCI 14691574

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*3 + *2/*2 + *2/*3 + *3/*3 methadone efficacy no No significant difference in genotype or phenotype frequencies between responders and non-responders, as defined by drug misuse during methadone maintenance therapy. No details about which specific variants/alleles were tested for. CYP2C9 *1/*3 + *2/*2 + *2/*3 + *3/*3 are not associated with response to methadone in people with Opioid-Related Disorders as compared to CYP2C9 *1/*1 + *1/*2. 21589866 1451161460
CYP2C9 CYP2C9*1, CYP2C9*3 *3 phenytoin dosage no In individuals who experienced severe cutaneous adverse reactions (SCARs) when taking phenytoin, the average daily dose of phenytoin was not significantly different between those who carried the CYP2C9*3 allele and those who did not. CYP2C9 *3 is not associated with dose of phenytoin in people with severe cutaneous adverse reactions as compared to CYP2C9 *1/*1. 25096692 1184989377
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*3 + *2/*2 + *2/*3 + *3/*3 methadone dosage no No significant difference in methadone dose between genotypes. No details about which specific variants/alleles were tested for. CYP2C9 *1/*3 + *2/*2 + *2/*3 + *3/*3 are not associated with dose of methadone in people with Opioid-Related Disorders as compared to CYP2C9 *1/*1 + *1/*2. 21589866 1451161642
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*3 + *2/*2 + *2/*3 + *3/*3 methadone metabolism/PK no No significant difference in concentrations of (R)-, (S)- or (R,S)-methadone between genotypes. No details about which specific variants/alleles were tested for. CYP2C9 *1/*3 + *2/*2 + *2/*3 + *3/*3 are not associated with concentrations of methadone in people with Opioid-Related Disorders as compared to CYP2C9 *1/*1 + *1/*2. 21589866 1451161652
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 phenytoin metabolism/PK yes No *3/*3 individuals were observed. CYP2C9 *1/*3 is associated with increased concentrations of phenytoin in people with Epilepsy as compared to CYP2C9 *1/*1. 14659971 1448994156
CYP2C9 CYP2C9*1, CYP2C9*3 *3 phenytoin metabolism/PK yes In individuals who experienced severe cutaneous adverse reactions (SCARs) when taking phenytoin, those who carried the CYP2C9*3 allele had significantly higher levels of plasma phenytoin, as compared to those who did not carry the *3 allele. CYP2C9 *3 is associated with increased concentrations of phenytoin in people with severe cutaneous adverse reactions as compared to CYP2C9 *1/*1. 25096692 1184989363
CYP2C9 CYP2C9*1, CYP2C9*17, CYP2C9*2 *1/*1 + *1/*2 + *1/*17 phenytoin metabolism/PK no No significant difference in dose-corrected phenytoin concentrations was seen between the *1/*1 and *1/*2 genotypes (p=0.90), or between the *1/*2 and *1/*17 genotypes (p=0.91). Univariate analysis. CYP2C9 *1/*1 + *1/*2 + *1/*17 are not associated with dose-adjusted trough concentrations of phenytoin in people with Epilepsy. 26122019 1445388514
CYP2C9 rs1057910 AC warfarin dosage yes There were no CC homozygotes. This variant is also known as *3. Also there were no rs1799853 carriers (*2). Genotype AC is associated with decreased dose of warfarin in people with Atrial Fibrillation as compared to genotype AA. 32559398 1451221905
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *2/*3 + *3/*3 siponimod metabolism/PK not stated The AUC ∞ and AUC last of siponimod were approximately two and fourfold higher in PMs (CYP2C9*2/*3 and CYP2C9*3/*3), respectively, compared with CYP2C9 EMs (CYP2C9*1/*1). The siponimod plasma T½ was also prolonged in subjects with the CYP2C9*2/*3 and CYP2C9*3/*3 genotypes (50.9 and 126 h, respectively) compared with EMs (CYP2C9*1/*1: 28.1 h), suggesting that the reduced CYP2C9 enzymatic activity does not affect the absorption phase of siponimod but prolongs the elimination phase. CYP2C9 *2/*3 + *3/*3 are associated with increased concentrations of siponimod in healthy individuals as compared to CYP2C9 *1/*1. 30088221 1451230861
CYP2C9 CYP2C9*8 *8 warfarin "dosage","metabolism/PK" not stated in a dosing algorithm to predict warfarin dosage (included age, BMI, thyroid status, CYP2C9; *2 (rs1799853), *3 (rs1057910), *8 (rs75838422) VKORC1; *3 (rs7294),*4 (rs17708472), -1639G>A (rs9923231), CYP4F2; V433M (rs2108622), GGCX; G8016A (rs699664). CYP2C9 *8 is associated with dose of warfarin. 22676192 978614420
CYP2C9 CYP2C9*3 *3 warfarin "dosage","metabolism/PK" not stated in a dosing algorithm to predict warfarin dosage (included age, BMI, thyroid status, CYP2C9; *2 (rs1799853), *3 (rs1057910), *8 (rs75838422) VKORC1; *3 (rs7294),*4 (rs17708472), -1639G>A (rs9923231), CYP4F2; V433M (rs2108622), GGCX; G8016A (rs699664). CYP2C9 *3 is associated with dose of warfarin. 22676192 978614436
CYP2C9 CYP2C9*1, CYP2C9*2 *2/*2 warfarin "dosage","efficacy" yes A model was created to predict maintenance doses for children of different ages, all with a baseline INR of 1 and a target INR of 2.5, based on longitudinal data from children taking warfarin. Due to the nature of the model, the quantitative CYP2C9 allele effects on clearance were assumed to be the same as for adults - n=2 children had the *2/*2 genotype in the data cohort. CYP2C9 genotype, VKORC1 genotype, bodyweight, age, baseline INR, target INR and time since initiation of therapy were all found to be significant causes of warfarin dose variability in children. This association is based on a table presenting results from the model predicting warfarin dose for children of 2, 8 and 14 years old with different rs9923231 genotype and CYP2C9 genotype presented in the paper. CYP2C9*2 was defined as rs1799853 and *3 as rs1057910. CYP2C9 *2/*2 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1/*1. 24330000 1184654383
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*1 warfarin dosage yes The mean warfarin dose was higher in patients with the *1/*1 genotype (3.5+/-2.0) as compared to those with the *1/*3 genotype (2.5+/-1.0). Additionally, this variant was included in an algorithm for determining warfarin dose. CYP2C9 *1/*1 is associated with increased dose of warfarin as compared to CYP2C9 *1/*3. 21326313 1448269030
CYP2C9 CYP2C9*1, CYP2C9*3 *3 simvastatin "dosage","metabolism/PK" yes This influence on the magnitude of the simvastatin-warfarin drug-drug interaction was seen only in patients with the CYP2C9*3 allele. Multiple regression model predicted that simvastatin exposure would have no effect in noncarriers, but reduces warfarin dose by 25% in heterozygous *3 carriers and by 43% in homozygous *3 carriers. (Genotyping details not provided). [stat_test: multiple regression analysis] CYP2C9 *3 is associated with decreased dose of warfarin when treated with simvastatin and warfarin. 22594507 827919897
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 warfarin dosage yes The study purpose was to develop a model for stable maintenance warfarin dose prediction. Most patients had a history of venous thromboembolism. CYP2C9 *1/*3 is associated with decreased dose of warfarin in people with venous thromboembolism as compared to CYP2C9 *1/*1. 20421126 1183701514
CYP2C9 CYP2C9*1, CYP2C9*2 *2 simvastatin "dosage","metabolism/PK" no Though *2 is associated with decreased dose of warfarin, it does not influence the magnitude of the simvastatin-warfarin drug-drug interaction on warfarin dose, which was seen only in patients with the CYP2C9*3 allele. (Genotyping details not provided). [stat_test: multiple regression analysis] CYP2C9 *2 is not associated with decreased dose of warfarin when treated with simvastatin and warfarin. 22594507 827919905
CYP2C9 CYP2C9*1, CYP2C9*3 *3/*3 warfarin "dosage","efficacy" yes A model was created to predict maintenance doses for children of different ages, all with a baseline INR of 1 and a target INR of 2.5, based on longitudinal data from children taking warfarin. Due to the nature of the model, the quantitative CYP2C9 allele effects on clearance were assumed to be the same as for adults - no children had the *3/*3 genotype in the data cohort. CYP2C9 genotype, VKORC1 genotype, bodyweight, age, baseline INR, target INR and time since initiation of therapy were all found to be significant causes of warfarin dose variability in children. This association is based on a table presenting results from the model predicting warfarin dose for children of 2, 8 and 14 years old with different rs9923231 genotype and CYP2C9 genotype presented in the paper. CYP2C9*2 was defined as rs1799853 and CYP2C9*3 as rs1057910. CYP2C9 *3/*3 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1/*1. 24330000 1184654356
CYP2C9 CYP2C9*1, CYP2C9*13, CYP2C9*3 *3/*13 warfarin dosage not stated This is a Korean patient with CYP2C9*3/*13 and VKORC1 1173TT genotypes who had slower than normal warfarin metabolism, resulting in the need to administer an extremely low dose of warfarin (4 mg/week) in order to achieve the target INR value. CYP2C9 *3/*13 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 21782804 1184510232
CYP2C9 CYP2C9*1, CYP2C9*3 *3 warfarin "dosage","metabolism/PK" yes [stat_test: multiple regression analysis] CYP2C9 *3 is associated with decreased dose of warfarin. 22594507 827919924
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 warfarin dosage yes Patients with the *1/*3 diplotype had a lower mean warfarin dose (2.7+/-0.9 mg/day) than those with the *1/*1 genotype (4.9+/-2.5 mg/day). Additionally, this study developed a pharmacogenetic algorithm for warfarin dosing in Korean patients and then compared it against other pharmacogenetic algorithms; this variant was present in the algorithm. CYP2C9 *1/*3 is associated with decreased dose of warfarin in people with Atrial Fibrillation. 21981797 1448267984
CYP2C9 CYP2C9*1, CYP2C9*3 *3 warfarin dosage yes in Korean patients with mechanical cardiac valves. CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1. 22549502 1184510026
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 warfarin "dosage","efficacy" yes A model was created to predict maintenance doses for children of different ages, all with a baseline INR of 1 and a target INR of 2.5, based on longitudinal data from children taking warfarin. Due to the nature of the model, the quantitative CYP2C9 allele effects on clearance were assumed to be the same as for adults - n=23 children had the *1/*3 genotype in the data cohort. CYP2C9 genotype, VKORC1 genotype, bodyweight, age, baseline INR, target INR and time since initiation of therapy were all found to be significant causes of warfarin dose variability in children. This association is based on a table presenting results from the model predicting warfarin dose for children of 2, 8 and 14 years old with different rs9923231 genotype and CYP2C9 genotype presented in the paper. CYP2C9*2 was defined as rs1799853 and *3 as rs1057910. CYP2C9 *1/*3 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1/*1. 24330000 1184654392
CYP2C9 CYP2C9*1, CYP2C9*2 *2 warfarin "dosage","metabolism/PK" yes [stat_test: multiple regression analysis] CYP2C9 *2 is associated with decreased dose of warfarin. 22594507 827919910
CYP2C9 CYP2C9*2 *2 warfarin "dosage","metabolism/PK" not stated in a dosing algorithm to predict warfarin dosage (included age, BMI, thyroid status, CYP2C9; *2 (rs1799853), *3 (rs1057910), *8 (rs75838422) VKORC1; *3 (rs7294),*4 (rs17708472), -1639G>A (rs9923231), CYP4F2; V433M (rs2108622), GGCX; G8016A (rs699664). CYP2C9 *2 is associated with dose of warfarin. 22676192 978614428
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*8 *1/*1 warfarin metabolism/PK yes Where *1/*2, *1/*3, and *1/*8 are intermediate metabolizers (IM), and *2/*3 and 2/*2 are poor metabolizers (PM). Extensive metabolizers (EM) required a higher median cumulative therapeutic dose of warfarin to reach the target international normalized ratio (INR), as compared to intermediate and poor metabolizers. 54% of the variability in dose was attributable to CYP2C9 genotype. Additionally, subjects who had a PM or IM genotype and the rs9923231 AA or AG genotype required the fewest days to reach target anticoagulation intensity (p=0.01) and the lowest median cumulative therapeutic dose of warfarin to reach the target international normalized ratio (INR) (p=0.007), as compared against patients with the EM + GG, EM + AG and IM/PM (specifically *1/*8 and *2/*3) + GG genotypes. CYP2C9 *1/*1 (assigned as normal metabolizers phenotype) is associated with increased dose of warfarin in healthy individuals as compared to CYP2C9 *1/*2 + *1/*3 + *1/*8 + *2/*3 + *2/*2 (assigned as poor metabolizers and intermediate metabolizers phenotype) . 24029542 1184511945
CYP2C9 rs28371686 G warfarin dosage yes This SNP defines CYP2C9*5. CYP2C9 *2,*3,*4,*5,*8 were grouped into three groups for testing: *1/*1 vs. *1/*2 + *1/*3 + *1/*4 + *1/*5 + *1/*8 vs *2/*2 + *2/*3 + *3/*3 + *5/*5. People having one or two variant alleles had lower dose requirements than people who were *1/*1. Allele G is associated with decreased dose of warfarin as compared to allele C. 21228733 827864554
CYP2C9 rs1057910 A warfarin dosage yes Samples, genotypes and INRs from a cohort of 551 patients were used to derive an algorithm which was used to predict daily warfarin maintenance dose in a second cohort of 236 patients. Note: the authors state that "SNPs were tested for deviations from HWE using the chi-squared test, and for their association with the warfarin dose by Spearman correlation analysis using a *co-dominant* model." rs1057910 remained significantly associated with warfarin maintenance dose in the multivariate analysis. Allele A is associated with increased dose of warfarin in people with heart valve replacement as compared to allele C. 25126975 1184756158
CYP2C9 rs1057910 AA warfarin dosage yes The goal of this study was to compare the accuracy of 8 different warfarin dosing algorithms, including the IWPC, and 6 Han Chinese PGx warfarin dosing algorithms, in Han Chinese patients taking warfarin scheduled to undergo mechanic heart valve replacement surgery. The authors concluded that the mean absolute error (MAE) of all algorithms was less than 0.6mg/day in initial and stable doses, and the percentage of patients whose actual doses were within 20% of their predicted dose was 45% for all algorithms. Predictive power of algorithms was highest for patients in the ideal-dose range and lowest for patients in the low and high dose range. The most accurate predictions came from three Han-Chinese PGx warfarin dosing algorithms (Du et al. 2010, Huang et al. 2009, Miao et al. 2007). Genotype AA is associated with increased dose of warfarin in people with Heart Valve Diseases as compared to genotype AC. 24728385 1184169096
CYP2C9 rs1799853 T phenprocoumon dosage no in pediatric patients. Allele T is not associated with dose of phenprocoumon and warfarin. 20833980 827864540
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*2 + *1/*3 methadone metabolism/PK yes The CYP2C9*2 allele was genotyped for using the variant rs1799853, while rs1057910 was used to detect the *3 allele. Individuals with the *1/*2 or *1/*3 genotype had significantly increased concentration/dose ratios of methadone. CYP2C9 *1/*2 + *1/*3 are associated with increased concentrations of methadone as compared to CYP2C9 *1/*1. 28723731 1451228747
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *2/*2 + *3/*3 methadone metabolism/PK no The CYP2C9*2 allele was genotyped for using the variant rs1799853, while rs1057910 was used to detect the *3 allele. Although individuals with the *2/*2 or *3/*3 genotypes had higher concentration/dose ratios of methadone compared to *1/*1, the difference was not statistically significant. CYP2C9 *2/*2 + *3/*3 are not associated with concentrations of methadone as compared to CYP2C9 *1/*1. 28723731 1451228780
CYP2C9 CYP2C9*1, CYP2C9*2 *1/*2 acenocoumarol dosage no Genotypes CYP2C9 *1/*2 or *1/*3 are not associated with dose of acenocoumarol as compared to genotypes *2/*2, *3/*3 or *2/*3. *1/*2 and *1/3 heterozygotes did not require significantly different weekly maintenance doses of acenocoumarol compared to variant allele homozygotes or compound heterozygotes. Maintenance doses were measured over at least a 3 month period during which stable anticoagulation had been achieved. Patients were treated with acenocoumarol for various unspecified indications. CYP2C9 *1/*2 is not associated with dose of acenocoumarol. 22486182 982010090
CYP2C9 CYP2C9*2 *2 acenocoumarol dosage no While carriers of the *2 allele did require a lower dose than wild-type patients, this difference was not statistically significant. CYP2C9 *2 is not associated with decreased dose of acenocoumarol as compared to CYP2C9 *1. 19018719 981940067
CYP2C9 CYP2C9*2 *2 acenocoumarol dosage no Please note; patients who were carriers of *2 were combined and compared against those who had genotype *1/*1. *3 was also genotyped for. The presence of a CYP2C9 inhibitor however significantly decreased dose, an effect which was stronger in patients with *3 or *2 than wildtype *1/*1 genotype. CYP2C9 *2 is not associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1. 23651023 982032876
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *2 + *3 acenocoumarol dosage not stated The novel algorithm to predict acenocoumarol dose in Romanian patients was first developed with 200 patients and validated in 101 patients. The algorithm included several variables. The CYP2C9 *2 and *3 polymorphisms explained 4.7% of dose variability. CYP2C9 *2 + *3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1. 23774941 1184754650
CYP2C9 CYP2C9*1, CYP2C9*2 *1/*2 acenocoumarol dosage no in North-Italian patients. CYP2C9 *1/*2 is not associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1. 14521618 1444707419
CYP2C9 CYP2C9*1, CYP2C9*3 *3 acenocoumarol dosage yes Normalized maintenance dose (NMD): mean maintenance dose/INR at equilibrium). A final multivariate regression model explained 48.1% of the global inter-individual variability in dose requirement. The authors created a clinical algorithm (CA) using patient’s clinical and demographic variables used in the PA. CYP2C9 *3 is associated with decreased dose of acenocoumarol in people with Atrial Fibrillation, Atrial Flutter or Venous Thrombosis as compared to CYP2C9 *1. 29479633 1449188274
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 acenocoumarol dosage no Genotypes CYP2C9 *1/*3 or *1/*2 are not associated with dose of acenocoumarol as compared to genotypes *2/*2, *3/*3 or *2/*3. *1/*3 and *1/2 heterozygotes did not require significantly different weekly maintenance doses of acenocoumarol compared to variant allele homozygotes or compound heterozygotes. Maintenance doses were measured over at least a 3 month period during which stable anticoagulation had been achieved. Patients were treated with acenocoumarol for various unspecified indications. CYP2C9 *1/*3 is not associated with dose of acenocoumarol. 22486182 982010097
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*3 + *3/*3 + *2/*3 acenocoumarol dosage yes No association with the CYP2C9*2 allele and acenocoumarol dose requirement was observed. CYP2C9 *1/*3 + *3/*3 + *2/*3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1. 11186138 1444707543
CYP2C9 CYP2C9*3 *3 acenocoumarol dosage yes Please note; patients who were carriers of *3 were combined and compared against those who had genotype *1/*1. *2 was also genotyped for. The presence of a CYP2C9 inhibitor also significantly decreased dose, an effect which was stronger in patients with *3 or *2 than wildtype *1/*1 genotype. CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1. 23651023 982031268
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*3 + *3/*3 + *2/*3 acenocoumarol dosage yes in North-Italian patients. CYP2C9 *1/*3 + *3/*3 + *2/*3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1. 14521618 1444707400
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *2 + *3 acenocoumarol dosage yes The *2 and *3 alleles were associated with decreased mean daily dose of acenocoumarol as compared to the *1 allele. The mean daily dose of individuals with the genotypes *1/*2 (N=12), *1/*3 (N=28), and *2/*3 (N=1) were 2.0 (+/-0.8) mg, 1.6 (+/- 0.7) mg, and 1.5 mg. The mean daily dose of individuals with the genotype *1/*1 (N=176) was 4.1 (+/-2.3) mg. In univariate and multivariate analysis the *2 and *3 alleles remained significantly associated with variability in acenocoumarol dose. CYP2C9 *2 + *3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1. 25519826 1444699553
CYP2C9 CYP2C9*2, CYP2C9*3 *2 + *3 acenocoumarol dosage yes CYP2C9 variants were significantly associated with acenocoumarol dose, and explained 11.7% of the variability in dose. Clinical variables (Age, BMI, Enzyme inducers status and Amiodarone status) explained 22% of the variability in dose. This study developed an algorithm for acenocoumarol dosing using clinical and pharmacogenetic data. CYP2C9 *2 + *3 is associated with dose of acenocoumarol. 22911785 1448259338
CYP2C9 CYP2C9*1, CYP2C9*2 *1/*2 + *2/*2 acenocoumarol dosage no No association with the CYP2C9*2 allele and acenocoumarol dose requirement was observed. CYP2C9 *1/*2 + *2/*2 are not associated with decreased dose of acenocoumarol. 11186138 1444707558
CYP2C9 CYP2C9*1 *1/*1 warfarin "dosage","metabolism/PK" yes CYP2C9 *1/*1 is associated with increased dose of warfarin in children as compared to CYP2C9 *1/*3. 22010099 982047396
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *2 + *3 warfarin dosage no In univariate analysis the weekly warfarin dose was most strongly associated with age, weight, height, BSA, sex, and VKORC1 genotype. There was a trend of association between the presence of 1 or 2 CYP2C9 variant alleles and decreased dose requirement but the association was not significant (this is the first reported p-value). After statistical adjustment for confounding variables the multivariate analysis showed that CYP2C9 genotype (number of variant * alleles, 0,1,2) explained 2% of the observed inter individual variability in warfarin dose (this is the second reported p-value). CYP2C9 *2 + *3 are associated with dose of warfarin in children as compared to CYP2C9 *1. 22130800 982047968
CYP2C9 CYP2C9*2, CYP2C9*3 *2 + *3 fluindione metabolism/PK no CYP2C9 *2 + *3 is not associated with dose of fluindione in children as compared to CYP2C9 *1/*1. 22130800 982047979
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*1 fluoxetine efficacy no No difference in response was observed between the CYP2C9 genotype groups. Five patients were classified as PM, with two defective alleles (*2/*3: n=3; *3*3: n=2). Twenty patients carried one defective allele and were classified as IM (*1/*2 or *1/*3). No defective alleles were detected in 58 patients identified as EM (*1/*1). CYP2C9 *1/*1 is not associated with response to fluoxetine in children with Depressive Disorder as compared to CYP2C9 *2/*3 + *3/*3. 24663076 1184472258
CYP2C9 CYP2C9*1, CYP2C9*2 *1/*2 warfarin "dosage","efficacy" yes A model was created to predict maintenance doses for children of different ages, all with a baseline INR of 1 and a target INR of 2.5, based on longitudinal data from children taking warfarin. Due to the nature of the model, the quantitative CYP2C9 allele effects on clearance were assumed to be the same as for adults - n=20 children had the *1/*2 genotype in the data cohort. CYP2C9 genotype, VKORC1 genotype, bodyweight, age, baseline INR, target INR and time since initiation of therapy were all found to be significant causes of warfarin dose variability in children. This association is based on a table presenting results from the model predicting warfarin dose for children of 2, 8 and 14 years old with different rs9923231 genotype and CYP2C9 genotype presented in the paper. CYP2C9*2 was defined as rs1799853 and *3 as rs1057910. CYP2C9 *1/*2 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1/*1. 24330000 1184654401
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*2 + *1/*3 + *2/*3 warfarin dosage yes Patients who carried the CYP2C9 *2 or *3 variant alleles required 71% the dose of warfarin as compared to those with the wild-type genotype. CYP2C9 genotype was found to account for 6% of the variability in stable warfarin dose (mg/day). CYP2C9 *1/*2 + *1/*3 + *2/*3 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1. 24601977 1185235722
CYP2C9 CYP2C9*1, CYP2C9*2 *2 warfarin dosage no The average daily warfarin dose required for maintenance therapy in patients with the CYP2C9*2 was 3.67±1.38, whereas it was 4.35±1.25 in those without this mutation. CYP2C9 *2 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1. 27182616 1448104659
CYP2C9 CYP2C9*1, CYP2C9*3 *3 warfarin dosage yes The average daily warfarin dose required for maintenance therapy in patients with the CYP2C9*3was 3.98±1.13, whereas it was 4.40±1.39 in those without this mutation. CYP2C9 *3 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1. 27182616 1448104673
CYP2C9 CYP2C9*1, CYP2C9*2 *2 warfarin dosage not stated CYP2C9 *2 is associated with dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1. 27453700 1448255577
CYP2C9 CYP2C9*1, CYP2C9*3 *3 warfarin dosage not stated CYP2C9 *3 is associated with dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1. 27453700 1448255587
CYP2C9 CYP2C9*3 *3 phenytoin dosage yes These alleles were found to influence target dose of phenytoin according to multiple regression analysis. It was also associated with a marked decrease in phenytoin metabolism. The overall model explained 74% of the variability in target dose. This study also did an analysis on the clinical usefulness of genotyping prior to phenytoin therapy. CYP2C9 *3 is associated with dose of phenytoin in children with Epilepsy. 25162219 1448265498
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 warfarin dosage yes Maintenance warfarin doses in pediatric patients with CYP2C9 *1/*3 genotype were 41% lower than doses in patients with the wild type allele (CYP2C9 *1/*1). CYP2C9 *1/*3 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1. 27661060 1448276106
CYP2C9 rs9332120 C carbamazepine efficacy yes Allele C is associated with increased response to carbamazepine, lamotrigine, phenytoin, primidone or valproic acid in children with Epilepsy as compared to allele T. 28343093 1448613053
CYP2C9 rs1057910 AA valproic acid dosage not stated Dosage did not differ between the three genotypes. The authors classified the A>C variant as *3. Genotype AA is not associated with dose of valproic acid in children with Epilepsy as compared to genotype AC. 23099353 1448634995
CYP2C9 rs1057910 AA valproic acid metabolism/PK not stated VPA plasma concentrations and VPA plasma concentrations adjusted by weight did not differ between the three genotypes.The authors classified the A>C variant as *3. Genotype AA is not associated with metabolism of valproic acid in children with Epilepsy as compared to genotype AC. 23099353 1448635002
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*3 + *2/*3 phenytoin metabolism/PK yes Patients who were heterozygous for the CYP2C9*3 allele had significantly higher levels of phenytoin than patients who did not carry the *3 allele. No patients with the *3/*3 diplotype were identified. CYP2C9 *1/*3 + *2/*3 are associated with increased concentrations of phenytoin in children with as compared to CYP2C9 *1/*1 + *1/*2. 27179628 1449565832
CYP2C9 CYP2C9*1, CYP2C9*2 *1/*2 phenytoin metabolism/PK no CYP2C9 *1/*2 is not associated with concentrations of phenytoin in children with as compared to CYP2C9 *1/*1. 27179628 1449565846
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*3 + *2/*3 phenytoin metabolism/PK no CYP2C9 *1/*3 + *2/*3 are not associated with dose of phenytoin in children with as compared to CYP2C9 *1/*1 + *1/*2. 27179628 1449565855
CYP2C9 CYP2C9*1, CYP2C9*2 *1/*2 phenytoin metabolism/PK no CYP2C9 *1/*2 is not associated with dose of phenytoin in children with as compared to CYP2C9 *1/*1. 27179628 1449565868
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *2 + *3 phenprocoumon dosage yes Authors noted that for CYP2C9*2/*3 there was a larger decrease in dose for patients with one variant allele (n=13) than for those with two variant alleles (n=2), relative to patients without variant alleles (n=26). CYP2C9 *2 + *3 is associated with decreased dose of phenprocoumon in children as compared to CYP2C9 *1. 30207196 1449747475
CYP2C9 rs1057910 C phenprocoumon dosage no in pediatric patients. Allele C is not associated with dose of phenprocoumon and warfarin. 20833980 827864544
CYP2C9 rs1057910 C phenytoin "other","metabolism/PK" no in vitro. Allele C is associated with decreased metabolism of phenytoin. 10901705 769250083
CYP2C9 rs1057910 C warfarin dosage yes Allele C is associated with decreased dose of warfarin as compared to allele A. 10961881 982033533
CYP2C9 CYP2C9*1, CYP2C9*2 *2 warfarin dosage yes in European americans, but not African americans. CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 26877068 1447952622
CYP2C9 rs7089580 AT warfarin dosage yes Genotype AT is associated with increased clearance of warfarin as compared to genotype AA. 25499099 1444608101
CYP2C9 rs1799853 T warfarin dosage yes This variant defines CYP2C9*2. Allele T is associated with decreased dose of warfarin as compared to allele C. 20072124 982037879
CYP2C9 CYP2C9*1, CYP2C9*3 *3 acenocoumarol dosage yes CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1. 26781925 1447681848
CYP2C9 rs1057910 C warfarin dosage yes Allele C is associated with decreased dose of warfarin as compared to allele A. 18535201 982032955
CYP2C9 rs4917639 C warfarin dosage yes Allele C is associated with decreased dose of warfarin as compared to allele A. 18535201 982032947
CYP2C9 rs10509680 T warfarin dosage yes Allele T is associated with decreased dose of warfarin as compared to allele G. 20833655 982033113
CYP2C9 CYP2C9*1 *1/*1 carvedilol "other","metabolism/PK" no CYP2C9 *1/*1 is not associated with metabolism of carvedilol in healthy individuals. 21599570 827807173
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *2/*3 + *3/*3 warfarin dosage yes CYP2C9 *2/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 22854539 1184509852
CYP2C9 CYP2C9*1, CYP2C9*11, CYP2C9*2, CYP2C9*5, CYP2C9*6 *2 + *6 + *5 + *11 warfarin dosage yes CYP2C9 *2 + *6 + *5 + *11 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 21590310 1184510263
CYP2C9 rs1057910 C losartan metabolism/PK yes Allele C is associated with decreased metabolism of losartan in people with no disease as compared to allele A. 11823761 769169634
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *2/*3 carvedilol "other","metabolism/PK" no CYP2C9 *2/*3 is not associated with metabolism of carvedilol in healthy individuals. 21599570 827807187
CYP2C9 CYP2C9*1, CYP2C9*3 *3 warfarin dosage yes CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 26777610 1447680533
CYP2C9 CYP2C9*1, CYP2C9*2 *2/*2 carvedilol "other","metabolism/PK" no CYP2C9 *2/*2 is not associated with metabolism of carvedilol in healthy individuals. 21599570 827807179
CYP2C9 CYP2C9*2 *2 acenocoumarol dosage not stated CYP2C9 *2 is associated with dose of acenocoumarol in people with a stable maintence dose. 22920394 981420009
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 carvedilol "other","metabolism/PK" no CYP2C9 *1/*3 is not associated with metabolism of carvedilol in healthy individuals. 21599570 827807184
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 + *3/*3 clopidogrel efficacy no CYP2C9 *1/*3 + *3/*3 is not associated with resistance to clopidogrel in people with Stroke as compared to CYP2C9 *1/*1. 26961113 1447949731
CYP2C9 CYP2C9*2, CYP2C9*3 *2/*3 warfarin dosage yes CYP2C9 *2/*3 is associated with decreased dose of warfarin in patients with heart valve replacement when treated with warfarin as compared to CYP2C9 *1/*1. 18836275 982044677
CYP2C9 rs1799853 T warfarin metabolism/PK not stated Impaired metabolism was found for S-warfarin. T= CYP2C9*2; C= CYP2C9*1. Allele T is associated with decreased metabolism of warfarin as compared to allele C. 8004131 1183701883
CYP2C9 CYP2C9*1, CYP2C9*11, CYP2C9*2, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*9 *2 + *6 + *5 + *11 warfarin dosage yes CYP2C9 *2 + *6 + *5 + *11 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1 + *1/*8 + *1/*9 + *9/*9. 21590310 1184510278
CYP2C9 rs1057910 C warfarin dosage yes Allele C is associated with decreased dose of warfarin. 19794411 608431732
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 + *3/*3 warfarin dosage yes CYP2C9 *1/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 23104259 1184483798
CYP2C9 rs7089580 T warfarin dosage yes Allele T is associated with increased dose of warfarin. 21270790 769245708
CYP2C9 CYP2C9*1, CYP2C9*3 *3/*3 warfarin dosage no In combination with VKORC1 rs9923231 TT. Doses for the 2 cases were 0.625 mg/d for case 1, and 1.25 mg/d for case 2. Target INRs 2-3. CYP2C9 *3/*3 is associated with decreased dose of warfarin in people with Atrial Fibrillation as compared to CYP2C9 *1/*1. 22040439 827783312
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*1 warfarin dosage yes Comparison of *1/*1 to (*1/*2, *1/*3) and to (*2/*2, *2/*3 and *3/*3) was significant as was comparison between *1/*1 to (*1/*2, *1/*3) and *1/*1 and (*2/*2, *2/*3 and *3/*3). CYP2C9 *1/*1 is associated with increased dose of warfarin as compared to CYP2C9 *2/*2 + *2/*3 + *3/*3 + *1/*2 + *1/*3. 23061746 981754835
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 + *3/*3 warfarin "dosage","efficacy" yes 2.1 mg/day vs 2.9 mg/day CYP2C9 *1/*3 + *3/*3 is associated with decreased dose of warfarin in people with mechanical heart valve replacement as compared to CYP2C9 *1/*1. 20653676 981483998
CYP2C9 CYP2C9*1, CYP2C9*3 *3 warfarin dosage yes This variant is evaluated along with VKORC1 rs7294 and ORM1 rs17650. CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1. 23208322 1184483457
CYP2C9 CYP2C9*3 *3 acenocoumarol dosage not stated CYP2C9 *3 is associated with dose of acenocoumarol in people with a stable maintence dose. 22920394 981420013
CYP2C9 CYP2C9*3 *3 acenocoumarol dosage yes Carriers of the *3 allele required a lower dose of acenocoumarol than wild-types patients in a statistically significant way. CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1. 19018719 981940074
CYP2C9 CYP2C9*3 *3 ibuprofen metabolism/PK yes Effect was seen for racemic mixture and S-IBU but not R-IBU. Effect was greatest for *3/*3 and intermediate for *1/*3 or *2/*3 as compared to *1/*1. CYP2C9 *3 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1. 12152005 981862003
CYP2C9 CYP2C9*2 *2 ibuprofen metabolism/PK no However, this was NOT significant when considered alone, ONLY when in combination with CYP2C8*3. Clearance was about half for *2/*2 than *1/*1 for racemic IBU. Clearance was about 50% for *2/*2 compared to *1/*1 for S-IBU and 41% for R-IBU. CYP2C9 *2 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1. 15289789 981862303
CYP2C9 CYP2C9*8 *8 acenocoumarol efficacy no No significant difference in INR after a single dose of acenocoumarol was seen among carriers of the variant alleles studied. CYP2C9 *8 is not associated with increased response to acenocoumarol as compared to CYP2C9 *1. 21811894 981940163
CYP2C9 CYP2C9*5 *5 acenocoumarol efficacy no No significant difference in INR after a single dose of acenocoumarol was seen among carriers of the variant alleles studied. CYP2C9 *5 is not associated with increased response to acenocoumarol as compared to CYP2C9 *1. 21811894 981940181
CYP2C9 CYP2C9*2 *2 acenocoumarol dosage no Patients with the *2 allele did not have higher odds of receiving lower doses of acenocoumarol. Age was an independent covariate that was significantly negatively associated with dose. CYP2C9 *2 is not associated with decreased dose of acenocoumarol as compared to CYP2C9 *1. 23159639 982006752
CYP2C9 CYP2C9*6 *6 acenocoumarol efficacy no No significant difference in INR after a single dose of acenocoumarol was seen among carriers of the variant alleles studied. CYP2C9 *6 is not associated with increased response to acenocoumarol as compared to CYP2C9 *1. 21811894 981940169
CYP2C9 CYP2C9*1, CYP2C9*8 *1/*8 losartan metabolism/PK no Subjects carrying the *8 allele did not show significantly different losartan/E3174 metabolic ratios as compared to subjects with the *1/*1 genotype. CYP2C9 *1/*8 is not associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1. 15289788 1134736215
CYP2C9 CYP2C9*3 *3 acenocoumarol dosage yes Patients carrying the *3 allele required significantly lower doses of acenocoumarol or phenprocoumon as compared to patients homozygous for the wild-type allele (*1/*1). CYP2C9 *3 is associated with decreased dose of acenocoumarol or phenprocoumon as compared to CYP2C9 *1. 20020283 1043818082
CYP2C9 CYP2C9*2 *2 phenprocoumon dosage no The effect on phenprocoumon dose due to the presence of the *2 allele did not reach statistical significance. CYP2C9 *2 is not associated with decreased dose of phenprocoumon as compared to CYP2C9 *1. 20376629 1043818268
CYP2C9 CYP2C9*2 *2 warfarin dosage yes CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1. 15883587 982043913
CYP2C9 CYP2C9*1, CYP2C9*5, CYP2C9*6 *1/*5 + *5/*6 losartan metabolism/PK yes Subjects carrying the *5 allele (*1/*5, *5/*6 and *5/*8) showed significantly higher losartan/E3174 metabolic ratios as compared to subjects with the *1/*1 genotype. CYP2C9 *1/*5 + *5/*6 is associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1. 15289788 1133417241
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *2 + *3 warfarin dosage yes CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1. 31653973 1451130680
CYP2C9 rs1057910 AC sulfamethoxazole metabolism/PK no CYP2C9 *1/*3 and *1/*1 genotypes were compared, and no significant difference in plasma sulfamethoxazole AUC (0-24hr) was seen. Genotype AC is not associated with metabolism of sulfamethoxazole in people with Kidney Transplantation as compared to genotype AA. 22106207 981477860
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*2 + *1/*3 + *2/*2 progesterone metabolism/PK no CYP2C9 *1/*2 + *1/*3 + *2/*2 are not associated with exposure to progesterone in women as compared to CYP2C9 *1/*1. 31482508 1451132005
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*2 + *1/*3 warfarin dosage yes CYP2C9 *1/*2 + *1/*3 is associated with decreased dose of warfarin when treated with warfarin as compared to CYP2C9 *1/*1. 19745563 982037353
CYP2C9 CYP2C9*3 *3 acenocoumarol dosage yes Patients with polymorphisms in the CYP2C9 gene (*2 or *3 alleles) needed lower maintenance doses of acenocoumarol. This effect was greater for the *3 allele than for the *2 allele. Old age and the presence of the *3 allele were independent predictors for low dose requirements. Patients with the CYP2C9*3 allele had an INR within the therapeutic range for a lower percentage of time than patients that were homozygous for the *1 allele. This association was not found for carriers of the *2 allele. CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1. 12414349 981934182
CYP2C9 CYP2C9*2 *2 acenocoumarol dosage yes Patients with variants in CYP2C9 (*2 or *3 alleles) were associated with a decreased maintenance dose of acenocoumarol as compared to the wildtype (*1/*1) haplotype. A gene-dose relationship exists showing that decreasing enzymatic activity of CYP2C9 results in a lower maintenance dose as follows: CYP2C9*1/*1 > *1/*2 > *1/*3 > *2/*2 > *2/*3. There were no *3 homozygotes found in this study. CYP2C9 *2 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1. 15128048 981934319
CYP2C9 CYP2C9*3 *3 phenprocoumon dosage no Patients with variants in CYP2C9 (*2 or *3 alleles) were not associated with a decreased maintenance dose of phenprocoumon as compared to the wildtype (*1/*1) haplotype. The authors suggest that phenprocoumon may be a useful clinical alternative to acenocoumarol for patients with CYP2C9 variants. CYP2C9 *3 is not associated with decreased dose of phenprocoumon as compared to CYP2C9 *1. 15128048 981934338
CYP2C9 CYP2C9*1, CYP2C9*3 *3 warfarin "dosage","metabolism/PK" yes Clearance of the S-warfarin enantiomer only is significant (10% of clearance seen by homozygous wild-type patients). Clearance of the R-warfarin enantiomer did not show differences among genotypes. The mean maintenance dose for patients homozygous for the *3 haplotype was 4.5 times lower than that of the *1 haplotype. CYP2C9 *3 is associated with decreased clearance of warfarin in people with Cardiovascular Diseases as compared to CYP2C9 *1. 12496751 981344716
CYP2C9 CYP2C9*3 *3 warfarin metabolism/PK yes Patients with *3 alleles are more frequently found in the low dose group, <26.25 mg/week. Four of the 22 subjects with one or more *3 alleles were found in the medium dose group, 26.25-43.75 mg/week, and none were found in the high dose group, >43.75 mg/week. CYP2C9 *3 is associated with decreased dose of warfarin in people with Cardiovascular Diseases. 12496751 981345093
CYP2C9 rs1057910 C warfarin dosage yes Allele C is associated with decreased dose of warfarin as compared to allele A. 27617219 1449258301
CYP2C9 CYP2C9*1, CYP2C9*3 *3/*3 celecoxib metabolism/PK yes Subjects with the *3/*3 genotype had decreased clearance (units = ml/h*kg), increased area under the curve from administration time to infinity (AUC; units = ng*h/ml), and increased elimination half-life (t1/2; units = hours) as compared to those with the *1/*1 genotype. However, no significant results for time to reach Cmax (Tmax; units = hours) were seen. CYP2C9 *3/*3 is associated with decreased clearance of celecoxib in healthy individuals as compared to CYP2C9 *1/*1. 23996211 1183680725
CYP2C9 CYP2C9*3 *3 warfarin dosage yes CYP2C9*2 and *3 explained 12% (P = 6.63 x 10(-34)) of the variation in warfarin dose. CYP2C9 *3 is associated with decreased dose of warfarin. 18574025 1183701116
CYP2C9 rs2153628 G indomethacin efficacy yes among neonates with patent ductus arteriosus (PDA). Allele G is associated with increased response to indomethacin as compared to allele A. 28609430 1451140040
CYP2C9 CYP2C9*9 *9 acenocoumarol efficacy no No significant difference in INR after a single dose of acenocoumarol was seen among carriers of the variant alleles studied. CYP2C9 *9 is not associated with increased response to acenocoumarol as compared to CYP2C9 *1. 21811894 981940156
CYP2C9 CYP2C9*11 *11 acenocoumarol efficacy no No significant difference in INR after a single dose of acenocoumarol was seen among carriers of the variant alleles studied. CYP2C9 *11 is not associated with increased response to acenocoumarol as compared to CYP2C9 *1. 21811894 981940175
CYP2C9 CYP2C9*3 *3 acenocoumarol dosage yes Patients with polymorphisms in the CYP2C9 gene (*2 or *3 alleles) needed lower maintenance doses of acenocoumarol. While this association was significant, it was stronger if the patient also had polymorphisms in the VKORC1 gene. Polymorphisms in VKORC1 had a greater effect on dose than polymorphisms in CYP2C9. Those patients with polymorphisms in both genes had a much higher risk of severe overanticoagulation than patients with one or no polymorphisms. Patients with the CYP2C9*3 allele had a lower probability of achieving dose stabilization. This association was not found for carriers of the *2 allele and was not affected by VKORC1 genotype. CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1. 16815313 981934149
CYP2C9 CYP2C9*1 *1/*1 warfarin "dosage","metabolism/PK" not stated Only one participant had the *2/*2 genotype CYP2C9 *1/*1 is associated with increased dose of warfarin in children as compared to CYP2C9 *2/*2. 22010099 982047409
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*2 + *2/*2 + *1/*3 + *2/*3 phenprocoumon dosage yes CYP2C9 *1/*2 + *2/*2 + *1/*3 + *2/*3 are associated with decreased dose of phenprocoumon as compared to CYP2C9 *1/*1. 24224579 1444707589
CYP2C9 rs9332131 del warfarin dosage yes Allele del is associated with decreased dose of warfarin. 20072124 608431785
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 warfarin dosage no This was one case report. The patient was also reported to demonstrate impaired clearance of S-warfarin. CYP2C9 *1/*3 is associated with decreased dose of warfarin. 15094935 1183701573
CYP2C9 rs28371685 T warfarin dosage yes Allele T is associated with decreased dose of warfarin as compared to allele C. 20072124 608431789
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 diclofenac metabolism/PK yes Healthy individuals with the *1/*3 genotype had a higher diclofenac/4'-OH diclofenac metabolite ratio, as compared to those with the *1/*1 genotype. No significant results were seen when considering the diclofenac/3'-OH metabolite ratio, or the diclofenac/5'-OH metabolite ratio. CYP2C9 *1/*3 is associated with decreased metabolism of diclofenac in healthy individuals as compared to CYP2C9 *1/*1. 23959274 1184510805
CYP2C9 rs4917639 A warfarin dosage yes This SNP explained 12% (P = 4.61 x 10(-30)) of the variation in warfarin dose. The direction of the allele:dose relationship is not given. Allele A is associated with dose of warfarin. 18574025 1183701274
CYP2C9 CYP2C9*3 *3 phenprocoumon "dosage","toxicity" yes Patients carrying the CYP2C9 *3 allele were found to have an increased risk of severe overanticoagulation, and required a lower maintenance dose of phenprocoumon as compared to patients homozygous for the *1 allele. CYP2C9 *3 is associated with decreased dose of phenprocoumon as compared to CYP2C9 *1. 15536456 1043737406
CYP2C9 rs28371686 G warfarin dosage yes Allele G is associated with decreased dose of warfarin as compared to allele C. 20072124 608431793
CYP2C9 rs7900194 A warfarin dosage yes Allele A is associated with decreased dose of warfarin as compared to allele G. 20072124 608431781
CYP2C9 rs1799853 T warfarin dosage yes Allele T is associated with decreased dose of warfarin. 19794411 608431758
CYP2C9 CYP2C9*3 *3 phenprocoumon metabolism/PK yes Patients with increasing numbers of low activity alleles (*2 or *3) showed significantly decreasing ratios between S- and R-phenprocoumon total clearances. CYP2C9 *3 is associated with decreased metabolism of phenprocoumon in healthy individuals as compared to CYP2C9 *1. 15128047 1028278039
CYP2C9 rs4086116 T acenocoumarol dosage yes from a GWAS study consisting of the index population of 1451 Caucasian subjects from the Rotterdam study and results were replicated in 287 subjects from the Rotterdam study extended cohort. Results were reported as dosage change of -2.9mg/week per additional variant allele but allele was not specified, assumed T based on MAF from dbSNP. Allele T is associated with decreased dose of acenocoumarol as compared to allele C. 19578179 769146304
CYP2C9 rs1057910 CC sulfonamides, urea derivatives efficacy yes Genotype CC is associated with increased response to sulfonamides, urea derivatives. 19794412 655385712
CYP2C9 rs1799853 TT sulfonamides, urea derivatives efficacy yes Genotype TT is associated with increased response to sulfonamides, urea derivatives. 19794412 655385709
CYP2C9 rs1057910 C warfarin dosage no Allele C is associated with decreased dose of warfarin. 19228618 655387562
CYP2C9 rs1057910 C warfarin dosage yes could only access abstract. Allele C is associated with decreased dose of warfarin as compared to allele A. 11127854 655388494
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *2 + *3 warfarin dosage yes CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 26739746 1447680551
CYP2C9 rs1799853 T phenytoin "dosage","metabolism/PK" no Allele T is not associated with increased dose of phenytoin in people with Epilepsy as compared to allele C. 15805193 613978599
CYP2C9 rs1057910 C phenytoin "dosage","metabolism/PK" yes Allele C is associated with increased dose of phenytoin in people with Epilepsy as compared to allele A. 15805193 613978582
CYP2C9 CYP2C9*1, CYP2C9*14 *1/*14 warfarin dosage not stated This patient also carries the warfarin insensitive VKORC1 -1639GG and CYP4F2 433Met/Met genotypes. CYP2C9 *1/*14 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 24956244 1184473659
CYP2C9 rs1799853 T warfarin dosage no Allele T is associated with decreased dose of warfarin. 19228618 655387565
CYP2C9 rs1057910 AC acenocoumarol other not stated Twenty-four hours after drug intake, INR and factor VII ratios were significantly different between genotype groups. CYP2C9*1/*1 (AA) INR: 1.24 plusminus 0.16; FVII ratio: 60 plusminus 19 CYP2C9*1/*3 (AC) INR: 1.42 plusminus 0.24; FVII ratio: 39 plusminus 17 Genotype AC is associated with response to acenocoumarol in healthy individuals as compared to genotype AA. 15116053 769169804
CYP2C9 rs1057910 AC warfarin dosage yes Genotype AC is associated with decreased dose of warfarin as compared to genotype AA. 28049362 1449192290
CYP2C9 CYP2C9*3 *3 ibuprofen metabolism/PK yes Clearance was about one fourth for *3/*3 than *1/*1 for racemic IBU. Clearance was about 25% for *3/*3 compared to *1/*1 for S-IBU and 16% for R-IBU. CYP2C9 *3 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1. 15289789 981862045
CYP2C9 CYP2C9*1, CYP2C9*58 *58 warfarin dosage not stated This variant was detected in a warfarin-hypersensitive patient with the maintenance dose of warfarin was 1.286 mg/day, 36% lower than normal dosing for han-chinese population. The enzymatic activity of the novel allelic variant has been greatly reduced. CYP2C9 *58 is associated with decreased dose of warfarin as compared to CYP2C9 *1. 25075423 1184482790
CYP2C9 rs9332131 del phenytoin "other","metabolism/PK" yes as measured by urinary excretion of its major metabolite, S-enantiomer of 5-(4-hydroxyphenyl)-5-phenylhydantoin (p-HPPH). Statistics given for trend with various PM allele vs *1*1. [stat_test: ANOVA] Allele del is associated with decreased metabolism of phenytoin in people with no disease as compared to genotype AA. 16220110 769249041
CYP2C9 rs7900194 A phenytoin "other","metabolism/PK" yes as measured by urinary excretion of its major metabolite, S-enantiomer of 5-(4-hydroxyphenyl)-5-phenylhydantoin (p-HPPH). Statistics given for trend with various PM allele vs *1*1. [stat_test: ANOVA] Allele A is associated with decreased metabolism of phenytoin in people with no disease as compared to genotype GG. 16220110 769249039
CYP2C9 rs28371685 T phenytoin "other","metabolism/PK" yes as measured by urinary excretion of its major metabolite, S-enantiomer of 5-(4-hydroxyphenyl)-5-phenylhydantoin (p-HPPH). Statistics given for trend with various PM allele vs *1*1. [stat_test: ANOVA] Allele T is associated with increased metabolism of phenytoin in people with no disease as compared to genotype CC. 16220110 769249040
CYP2C9 rs28371686 G phenytoin "other","metabolism/PK" yes as measured by urinary excretion of its major metabolite, S-enantiomer of 5-(4-hydroxyphenyl)-5-phenylhydantoin (p-HPPH). Statistics given for trend with various PM allele vs *1*1. [stat_test: ANOVA] Allele G is associated with decreased metabolism of phenytoin in people with no disease as compared to genotype CC. 16220110 769249016
CYP2C9 rs1799853 T phenytoin "other","metabolism/PK" no in vitro. Allele T is not associated with decreased metabolism of phenytoin. 10901705 769250082
CYP2C9 rs1799853 CT phenytoin metabolism/PK yes as measured by urinary (S)-p-HPPH. [stat_test: Kruskal Wallis]. One individual genotyped to be CYP2C9*2/*3 (rs1799853T and rs1057910C) had even lower (S)-p-HPPH and (R)-p-HPPH ratio. Genotype CT is associated with decreased metabolism of phenytoin in people with Epilepsy as compared to genotype CC. 16815679 769250028
CYP2C9 rs1057910 AA + AC warfarin dosage yes "The mean warfarin dose in patients with the CYP2C9 rs1057910AA genotype was 3.34 mg/day, which was higher than that in patients with the CYP2C9 rs1057910CC genotype (0.81 mg/day)." Genotypes AA + AC is associated with increased dose of warfarin as compared to genotype CC. 23941071 1184482810
CYP2C9 rs12782374 AG phenytoin "other","metabolism/PK" not stated in human liver samples from individuals who did not have CYP2C9*2(rs1799853 T) or *3 (rs1057910 C). Measured by ratio of formation of (S)- and (R)-p-HPPH in vitro. Genotype AG is associated with increased metabolism of phenytoin as compared to genotype GG. 19855097 769250167
CYP2C9 rs12782374 A warfarin "dosage","metabolism/PK" no after excluding those patients carrying CYP2C9*2, *3, and VKORC1 variant alleles. Allele A is not associated with dose of warfarin in people with stable INRs in target range of 2-3 as compared to allele G. 19855097 769250174
CYP2C9 rs71486745 GT/del + del/del phenytoin "dosage","metabolism/PK" yes Statistics given for haplotype *1B measured by rs71486745delTG and rs12782374G>A. Genotypes GT/del + del/del are associated with decreased dose of phenytoin in people with Epilepsy as compared to genotype GTGT. 19855097 769250171
CYP2C9 rs12782374 AA + AG phenytoin "dosage","metabolism/PK" yes Statistics given for haplotype *1B measured by rs71486745delTG and rs12782374G>A. Genotypes AA + AG are associated with decreased dose of phenytoin in people with Epilepsy as compared to genotype GG. 19855097 769250168
CYP2C9 rs71486745 del warfarin "dosage","metabolism/PK" no after excluding those patients carrying CYP2C9*2, *3, and VKORC1 variant alleles. Allele del is not associated with dose of warfarin in people with stable INRs in target range of 2-3 as compared to allele GT. 19855097 769250177
CYP2C9 CYP2C9*1, CYP2C9*3 *3/*3 + *1/*3 warfarin dosage yes in Han-Chinese patients with mechanical heart valve replacement. CYP2C9 *3/*3 + *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 23949431 1184482762
CYP2C9 rs1057910 C warfarin dosage yes CYP2C9*3 was associated with a 33% (95% confidence interval 29¿37%) decrement in warfarin dose per allele. Allele C is associated with decreased dose of warfarin as compared to allele A. 18305455 827602228
CYP2C9 rs1799853 T warfarin dosage yes CYP2C9*2 is associated with a 19% decrement in the warfarin dose per allele. Allele T is associated with decreased dose of warfarin as compared to allele C. 18305455 827602050
CYP2C9 rs771237265 C tolbutamide metabolism/PK yes In vitro analysis showed that intrinsic clearance of tolbutamide by CYP2C9 protein containing the C allele was 9.6% of that of the WT protein. Variant referred to as 343A>C in the paper. Allele C is associated with decreased clearance of tolbutamide as compared to allele A. 30745309 1450935696
CYP2C9 rs761895497 C tolbutamide metabolism/PK yes In vitro analysis showed that intrinsic clearance of tolbutamide by CYP2C9 protein containing the C allele was 43.6% of that of the WT protein. Variant referred to as 791T>C in the paper. Allele C is associated with decreased clearance of tolbutamide as compared to allele T. 30745309 1450935701
CYP2C9 rs1057910 AC glimepiride "dosage","metabolism/PK" no The study noted a trend for a lower stable dose in CYP2C9*3 carriers (*1/*3 (AC) or *2/*3) compared to CYP2C9*1 homozygotes (AA), though this did not reach statistical significance. Genotype AC is associated with decreased dose of glimepiride in people with Diabetes Mellitus, Type 2 as compared to genotype AA. 21121772 827695929
CYP2C9 CYP2C9*2 *2 acenocoumarol efficacy yes CYP2C9 wild-type patients were found to be at an increased risk of subtherapeutic anticoagulation when compared to patients carrying at least one variant allele (*2 or *3). This effect was present during the first month of therapy. This risk is increased if the patient is also wild-type for the VKORC1 gene, which had a greater effect on the risk of underanticoagulation. Similarly, patients carrying variants of the CYP2C9 gene had a higher risk of overanticoagulation. CYP2C9 *2 is associated with increased response to acenocoumarol as compared to CYP2C9 *1. 22252093 981954118
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*2 + *1/*3 warfarin dosage no The authors state that "CYPC29 accounted for 5%" of dosing variability in the full multiple linear regression model. (as compared to VKORC1 which accounted for 47% of dosing variability, and age and target INR which contribute about 30%). CYP2C9 *1/*2 + *1/*3 is not associated with dose of warfarin in children as compared to CYP2C9 *1/*1. 23183958 981858924
CYP2C9 rs1057910 C warfarin "dosage","metabolism/PK" yes Allele C is associated with decreased dose of warfarin as compared to allele A. 19300499 827641903
CYP2C9 rs1799853 T warfarin "dosage","metabolism/PK" yes Allele T is associated with decreased dose of warfarin as compared to allele C. 19300499 827641894
CYP2C9 rs7089580 T warfarin dosage yes Allele T is associated with decreased dose of warfarin in children as compared to allele A. 24474498 1184472932
CYP2C9 rs1057910 AC warfarin dosage yes Genotype AC is associated with decreased dose of warfarin as compared to genotype AA. 17111199 827658659
CYP2C9 rs1799853 CT warfarin dosage yes Genotype CT is associated with decreased dose of warfarin as compared to genotype CC. 17111199 827657784
CYP2C9 rs1057910 AC + CC warfarin "dosage","metabolism/PK" yes Genotypes AC + CC are associated with decreased dose of warfarin as compared to genotype AA. 16432637 827661941
CYP2C9 CYP2C9*1, CYP2C9*3 *3/*3 + *1/*3 warfarin dosage yes in han chinese. CYP2C9 *3/*3 + *1/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 27488389 1448257090
CYP2C9 CYP2C9*1, CYP2C9*2 *2/*2 warfarin dosage yes Genotyped for rs1799853 and rs1057910. Combined *2/*2, *2/*3 and *3*3 were compared with carriers of the *1 allele. [stat_test: kruskal-wallis] CYP2C9 *2/*2 is associated with decreased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to CYP2C9 *1/*1. 21174619 827783860
CYP2C9 CYP2C9*1, CYP2C9*3 *3/*3 warfarin dosage yes Genotyped for rs1799853 and rs1057910. Combined *2/*2, *2/*3 and *3*3 were compared with carriers of the *1 allele. [stat_test: kruskal-wallis] CYP2C9 *3/*3 is associated with decreased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to CYP2C9 *1/*1. 21174619 827783868
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *2/*3 warfarin dosage yes Genotyped for rs1799853 and rs1057910. Combined *2/*2, *2/*3 and *3*3 were compared with carriers of the *1 allele. [stat_test: kruskal-wallis] CYP2C9 *2/*3 is associated with decreased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to CYP2C9 *1/*1. 21174619 827783863
CYP2C9 CYP2C9*1, CYP2C9*2 *1/*2 carvedilol "other","metabolism/PK" no CYP2C9 *1/*2 is not associated with metabolism of carvedilol in healthy individuals. 21599570 827807176
CYP2C9 CYP2C9*1, CYP2C9*2 *2 clopidogrel efficacy no All patients were on double-antiplatelet therapy (aspirin, 125 mg/day; clopidogrel, 75 mg/day) at least 7 days before carotid artery stenting. CYP2C9 *2 is not associated with response to clopidogrel in people with Carotid Artery Diseases as compared to CYP2C9 *1. 26526111 1448115817
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 + *3/*3 warfarin dosage yes CYP2C9 *1/*3 + *3/*3 are associated with decreased dose of warfarin in people with heart valve replacement as compared to CYP2C9 *1/*1. 28079798 1448567637
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 warfarin "dosage","metabolism/PK" yes No *3*3 homozygotes were observed. Daily maintenance dose range for *1*1 was 3.00 to 3.42mg/day, dose range for *1*3 was 1.47 to 2.55mg/day. CYP2C9 *1/*3 is associated with decreased dose of warfarin in people with Thromboembolism as compared to CYP2C9 *1/*1. 22528326 827925130
CYP2C9 rs1057910 C warfarin dosage yes C = CYP2C9*3. A = CYP2C9*1. *2 and *3 were pooled together in this comparison to *1. CYP2C9(*2 + *3) were associated with a lower maintenance dose (2.9 vs 3.7 mg for *1). [stat_test:linear regression] Allele C is associated with decreased dose of warfarin as compared to allele A. 21110192 827823825
CYP2C9 rs1057910 AC warfarin dosage yes warfarin-maintenance dose. also referred to as CYP2C9*3 (allele C). No individuals in the cohort had the genotype CYP2C9*3/*3 (CC). Genotype AC is associated with decreased dose of warfarin in people with an international normalized ratio (INR) of 2.0-3.0 as compared to genotype AA. 22248286 827845798
CYP2C9 CYP2C9*3 *3 acenocoumarol efficacy yes Subjects with the *3 allele were found to have lower factor VII levels and higher INR changes when compared to subjects with the wildtype allele. This information was gained from a previous study from this group with the same cohort (PMID: 15116053) but was reiterated here. CYP2C9 *3 is associated with increased response to acenocoumarol in healthy individuals as compared to CYP2C9 *1. 15790782 981865137
CYP2C9 rs9332127 C warfarin dosage no No association was found between this variant and warfarin-maintenance dose. Allele C is not associated with increased dose of warfarin in people with an international normalized ratio (INR) of 2.0-3.0 as compared to allele G. 22248286 827845815
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*3 warfarin dosage yes CYP2C9 *1/*3 is associated with decreased dose of warfarin in patients with heart valve replacement when treated with warfarin as compared to CYP2C9 *1/*1. 18836275 982044655
CYP2C9 rs72558187 C warfarin dosage no No association was found between this variant and warfarin-maintenance dose. Described as CYP2C9*13 in this study. Allele C is not associated with increased dose of warfarin in people with an international normalized ratio (INR) of 2.0-3.0 as compared to allele T. 22248286 827845924
CYP2C9 CYP2C9*1 *1/*1 warfarin dosage yes as compared to *2*2 or *3*3 or *2*3 with *1*2 and *1*3 requiring intermediate doses. This was most marked at day 28 to end of follow-up with average doses of 5.18mg/day for *1*1, 4.25mg/day for *1*2 or *1*3 and 3.36mg/day for *2*2 or *3*3 or *2*3. CYP2C9 *1/*1 is associated with increased dose of warfarin. 18322281 827807419
CYP2C9 rs1057910 CC celecoxib metabolism/PK yes Genotype CC is associated with a 3-fold decreased oral clearance of celecoxib and a 1.5-fold prolonged elimination half-life as compared to genotype AA. Genotype CC is associated with decreased clearance of celecoxib in healthy individuals as compared to genotype AA. 12893985 1183690931
CYP2C9 rs1799853 T warfarin dosage yes This SNP defines CYP2C9*2. CYP2C9 *2,*3,*4,*5,*8 were grouped into three groups for testing: *1/*1 vs. *1/*2 + *1/*3 + *1/*4 + *1/*5 + *1/*8 vs *2/*2 + *2/*3 + *3/*3 + *5/*5. People having one or two variant alleles had lower dose requirements than people who were *1/*1. Allele T is associated with decreased dose of warfarin as compared to allele C. 21228733 827864546
CYP2C9 rs1057910 C sulfonamides, urea derivatives efficacy no Allele C is not associated with response to sulfonamides, urea derivatives in people with Diabetes Mellitus as compared to allele A. 29681852 1449310660
CYP2C9 rs1057910 C warfarin dosage not stated Allele C is associated with dose of warfarin as compared to allele A. 28973620 1449269204
CYP2C9 rs1799853 T warfarin dosage not stated Allele T is associated with dose of warfarin as compared to allele C. 28973620 1449269199
CYP2C9 CYP2C9*1, CYP2C9*3 *3 warfarin "other","metabolism/PK" not stated For S-Warfarin in a model that included bodyweight, age and sex. CYP2C9 *3 is associated with decreased clearance of warfarin as compared to CYP2C9 *1. 21692828 827863693
CYP2C9 CYP2C9*1, CYP2C9*2 *2 warfarin "other","metabolism/PK" not stated For S-Warfarin in a model that included bodyweight, age and sex. CYP2C9 *2 is associated with decreased clearance of warfarin as compared to CYP2C9 *1. 21692828 827863698
CYP2C9 rs1057910 C warfarin dosage yes Allele C is associated with decreased dose of warfarin as compared to allele A. 21148049 827814740
CYP2C9 rs1057910 C acenocoumarol dosage no in Lebanese participants on long-term acenocoumarol therapy. (weak p value 0.057) Allele C is associated with decreased dose of acenocoumarol as compared to allele A. 21148049 827814749
CYP2C9 rs4086116 T phenprocoumon dosage yes Each additional CYP2C9 variant allele reduced phenprocoumon maintenance dosage by 2.2 mg/week (P=0.002).The study found additive effects of the variant alleles of CYP2C9 (rs4086116) and CYP4F2 (rsrs2108622) on VKORC1. Allele T is associated with decreased dose of phenprocoumon maintenance dosage by 2.2 mg/week as compared to allele C. 21063236 827807860
CYP2C9 rs1799853 T acenocoumarol dosage not stated in Lebanese participants on long-term warfarin or acenocoumarol maintenance therapy irrespective of VKORC1 genotypes. CYP2C9*2 had the least impact on the response to both drugs as compared to CYP2C9*3 and VKORC1 rs9923231. Allele T is not associated with decreased dose of acenocoumarol or warfarin as compared to allele C. 21148049 827814765
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*3 + *2/*3 warfarin dosage yes Genetic variants in CYP2C9 contributed to 12.4% of the variation in warfarin dose. CYP2C9 *1/*3 + *2/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 24019055 1183704662
CYP2C9 rs1799853 T warfarin dosage yes T = CYP2C9*2. C = CYP2C9*1. *2 and *3 were pooled together in this comparison to *1. CYP2C9(*2 + *3) were associated with a lower maintenance dose (2.9 vs 3.7 mg for *1). [stat_test:linear regression] Allele T is associated with decreased dose of warfarin as compared to allele C. 21110192 827823816
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 warfarin dosage yes in patients early after heart valve replacement surgery. CYP2C9 *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 31444512 1450935601
CYP2C9 CYP2C9*1, CYP2C9*2 *2 warfarin dosage no in Alaska Native and American Indian People. CYP2C9 *2 is not associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 30821933 1450370774
CYP2C9 CYP2C9*1, CYP2C9*3 *3 warfarin dosage no in Alaska Native and American Indian People. CYP2C9 *3 is not associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 30821933 1450370787
CYP2C9 CYP2C9*1, CYP2C9*2 *2 fluvastatin metabolism/PK yes This variant is significantly associated with increased area under the plasma concentration-time curve (AUC) of both 3R,5S-fluvastatin and 3S,5R-fluvastatin and total fluvastatin in the candidate gene study. CYP2C9 *2 is associated with increased concentrations of fluvastatin in healthy individuals as compared to CYP2C9 *1/*1. 30989645 1450823501
CYP2C9 CYP2C9*1, CYP2C9*3 *3 warfarin dosage yes Minor allele frequency was 5.1%, with only one homozygote (*3/*3). *2 and *3 were tested but very small numbers of *2 (2 heterozygotes and no homozygotes, frequency of 0.5%) meant that *2 was not significant. CYP2C9 *3 is associated with decreased dose of warfarin in people with Atrial Fibrillation, Pulmonary Embolism or Venous Thrombosis as compared to CYP2C9 *1/*1. 31854268 1450939860
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*3 + *2/*2 + *2/*3 + *3/*3 phenytoin metabolism/PK yes Compared to CYP2C9 extensive metabolizers, low-intermediate/poor metabolizers had a 21.3-pg/mL increase (95% CI: 13.6–29.0pg/mL; P<0.01) CYP2C9 *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased concentrations of phenytoin as compared to CYP2C9 *1/*1. 31461080 1450969200
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 naproxen metabolism/PK no looking at clearance, plasma drug levels and half life. There were no *3*3 homozygotes, 14 were *1*1, 6 were *1*3. CYP2C9 *1/*3 is not associated with clearance of naproxen in men with no disease as compared to CYP2C9 *1/*1. 19280158 981478337
CYP2C9 rs1057910 C warfarin dosage yes Allele C is associated with decreased dose of warfarin as compared to allele A. 19752777 1447519932
CYP2C9 rs7900194 A warfarin dosage yes This SNP defines CYP2C9*8. CYP2C9 *2,*3,*4,*5,*8 were grouped into three groups for testing: *1/*1 vs. *1/*2 + *1/*3 + *1/*4 + *1/*5 + *1/*8 vs *2/*2 + *2/*3 + *3/*3 + *5/*5. People having one or two variant alleles had lower dose requirements than people who were *1/*1. Allele A is associated with decreased dose of warfarin as compared to allele G. 21228733 827864548
CYP2C9 CYP2C9*1, CYP2C9*2 *2 warfarin "dosage","metabolism/PK" yes Clearance of the S-warfarin enantiomer only is significant (33% of clearance seen by homozygous wild-type patients). Clearance of the R-warfarin enantiomer did not show differences among haplotypes. The mean maintenance dose for patients homozygous for the *2 haplotype was 1.9 times lower than that of the *1 haplotype. CYP2C9 *2 is associated with decreased clearance of warfarin in people with Cardiovascular Diseases as compared to CYP2C9 *1. 12496751 981344709
CYP2C9 rs1057910 AA warfarin dosage yes Analysis was performed on stable warfarin dose. Genotype AA is associated with increased dose of warfarin in people with heart valve replacement as compared to genotype AC. 26223945 1448431507
CYP2C9 CYP2C9*2 *2 warfarin metabolism/PK yes Patients with *2 alleles are more frequently found in the low or medium dose groups, <26.25 mg/week or 26.25-43.75 mg/week, respectively. Only one of the 21 subjects with one or more *2 alleles was found in the high dose group, >43.75 mg/week. CYP2C9 *2 is associated with decreased dose of warfarin in people with Cardiovascular Diseases. 12496751 981345061
CYP2C9 CYP2C9*2 *2 phenprocoumon dosage no Patients with variants in CYP2C9 (*2 or *3 alleles) were not associated with a decreased maintenance dose of phenprocoumon as compared to the wildtype (*1/*1) haplotype. The authors suggest that phenprocoumon may be a useful clinical alternative to acenocoumarol for patients with CYP2C9 variants. CYP2C9 *2 is not associated with decreased dose of phenprocoumon as compared to CYP2C9 *1. 15128048 981934332
CYP2C9 CYP2C9*3 *3 acenocoumarol dosage yes Patients with variants in CYP2C9 (*2 or *3 alleles) were associated with a decreased maintenance dose of acenocoumarol as compared to the wildtype (*1/*1) haplotype. A gene-dose relationship exists showing that decreasing enzymatic activity of CYP2C9 results in a lower maintenance dose as follows: CYP2C9*1/*1 > *1/*2 > *1/*3 > *2/*2 > *2/*3. There were no *3 homozygotes found in this study. CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1. 15128048 981934326
CYP2C9 CYP2C9*1 *1/*1 acenocoumarol dosage yes As compared to patients with the genotypes CYP2C9 *1/*2 or *1/*3. *1/*1 homozygotes required significantly higher weekly maintenance doses of acenocoumarol compared to variant allele carriers. Maintenance doses were measured over at least a 3 month period during which stable anticoagulation had been achieved. Patients were treated with acenocoumarol for various unspecified indications. CYP2C9 *1/*1 is associated with increased dose of acenocoumarol. 22486182 982010010
CYP2C9 CYP2C9*2 *2 acenocoumarol dosage yes Patients with polymorphisms in the CYP2C9 gene (*2 or *3 alleles) needed lower maintenance doses of acenocoumarol. This effect was greater for the *3 allele than for the *2 allele. Old age and the presence of the *3 allele were independent predictors for low dose requirements. Patients with the CYP2C9*3 allele had an INR within the therapeutic range for a lower percentage of time than patients that were homozygous for the *1 allele. This association was not found for carriers of the *2 allele. CYP2C9 *2 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1. 12414349 981934227
CYP2C9 CYP2C9*2 *2 acenocoumarol dosage yes Patients with polymorphisms in the CYP2C9 gene (*2 or *3 alleles) needed lower maintenance doses of acenocoumarol. While this association was significant, it was stronger if the patient also had polymorphisms in the VKORC1 gene. Polymorphisms in VKORC1 had a greater effect on dose than polymorphisms in CYP2C9. Those patients with polymorphisms in both genes had a much higher risk of severe overanticoagulation than patients with one or no polymorphisms. Patients with the CYP2C9*3 allele had a lower probability of achieving dose stabilization. This association was not found for carriers of the *2 allele and was not affected by VKORC1 genotype. CYP2C9 *2 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1. 16815313 981934157
CYP2C9 CYP2C9*2 *2 ibuprofen metabolism/PK no CYP2C9 *2 is not associated with clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1. 12152005 981862010
CYP2C9 CYP2C9*3 *3 acenocoumarol efficacy yes CYP2C9 wild-type patients were found to be at an increased risk of subtherapeutic anticoagulation when compared to patients carrying at least one variant allele (*2 or *3). This effect was present during the first month of therapy. This risk is increased if the patient is also wild-type for the VKORC1 gene, which had a greater effect on the risk of underanticoagulation. Similarly, patients carrying variants of the CYP2C9 gene had a higher risk of overanticoagulation. CYP2C9 *3 is associated with increased response to acenocoumarol as compared to CYP2C9 *1. 22252093 981954134
CYP2C9 CYP2C9*3 *3 acenocoumarol dosage yes Patients with the *3 allele had much higher odds of receiving lower doses of acenocoumarol. Age was an independent covariate that was significantly negatively associated with dose. CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1. 23159639 982006745
CYP2C9 CYP2C9*1 *1 acenocoumarol dosage no No significant difference was seen between the daily dose for CYP2C9 wildtype patients and the daily dose for CYP2C9 variant carriers. This study provides an algorithm for predicting the maintenance dose of acenocoumarol using genotypes as well as clinical factors as predictive variables. CYP2C9 *1 is not associated with increased dose of acenocoumarol as compared to CYP2C9 *2 + *3. 22629463 981954438
CYP2C9 CYP2C9*1 *1/*1 acenocoumarol dosage yes As compared to patients with the genotypes CYP2C9 *2/*2, *3/*3 or *2/*3. *1/*1 homozygotes required significantly higher weekly maintenance doses of acenocoumarol compared to variant allele homozygotes or compound heterozygotes. Maintenance doses were measured over at least a 3 month period during which stable anticoagulation had been achieved. Patients were treated with acenocoumarol for various unspecified indications. CYP2C9 *1/*1 is associated with increased dose of acenocoumarol. 22486182 982010082
CYP2C9 CYP2C9*3 *3 acenocoumarol dosage yes Patients with lower functioning CYP2C9 enzymes (carrying the *2 or *3 alleles) required lower doses to reach a stable INR in the therapeutic range. Variants in the VKORC1 gene were shown to have a greater affect on dose than CYP2C9 variants. Age and BMI are clinical covariates that also statistically significantly affected maintenance dose. CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1. 23473641 982015087
CYP2C9 CYP2C9*2 *2 acenocoumarol dosage yes Patients with lower functioning CYP2C9 enzymes (carrying the *2 or *3 alleles) required lower doses to reach a stable INR in the therapeutic range. Variants in the VKORC1 gene were shown to have a greater affect on dose than CYP2C9 variants. Age and BMI are clinical covariates that also statistically significantly affected maintenance dose. CYP2C9 *2 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1. 23473641 982015075
CYP2C9 CYP2C9*1, CYP2C9*6 *1/*6 losartan metabolism/PK not stated Subjects carrying the *6 allele showed losartan/E3174 metabolic ratios outside of the 95% confidence interval of metabolic ratios for subjects homozygous for the wildtype allele (*1/*1). CYP2C9 *1/*6 is associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1. 15289788 1134049001
CYP2C9 CYP2C9*1, CYP2C9*11 *1/*11 losartan metabolism/PK no Subjects carrying the *11 allele did not show significantly different losartan/E3174 metabolic ratios as compared to subjects with the *1/*1 genotype. CYP2C9 *1/*11 is not associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1. 15289788 1134807206
CYP2C9 CYP2C9*1, CYP2C9*2 *1/*2 losartan metabolism/PK no Subjects carrying the *2 allele showed higher losartan/E3174 metabolic ratios as compared to patients with the *1 allele, though this association lacked significance. This study determined that losartan would be a safe drug for use as a CYP2C9 activity probe. CYP2C9 *1/*2 is not associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1. 15197523 1043880897
CYP2C9 CYP2C9*3 *3 warfarin dosage yes CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1. 15883587 982043919
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*3 losartan efficacy yes Patients with secondary kidney diseases carrying CYP2C9 variant alleles (*2 or *3) showed increases in blood pressure (both systolic and diastolic) as compared to patients with the *1/*1 genotype. A nonsignificant trend towards improved urinary protein excretion was seen in patients with primary kidney diseases with the *1/*1 genotype as compared to patients carrying variant alleles (*2 or *3). CYP2C9 *1/*3 is associated with decreased response to losartan in people with Kidney Diseases as compared to CYP2C9 *1/*1. 19669737 1183490988
CYP2C9 CYP2C9*3 *3 phenprocoumon "dosage","metabolism/PK" yes Daily dose of phenprocoumon is not significantly associated with CYP2C9 genotype. Daily dose is negatively correlated with age. This study published an algorithm for daily dose that includes height, although height was not significant in univariate analysis. This haplotype is significantly associated with higher phenprocoumon concentration as compared to patients with the wildtype haplotype. CYP2C9 *3 is associated with decreased metabolism of phenprocoumon as compared to CYP2C9 *1. 21110013 982046666
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5 *1/*2 + *1/*3 + *2/*3 + *2/*2 + *1/*5 + *2/*5 warfarin dosage yes This variant is analyzed along with VKORC1 variants. CYP2C9 *1/*2 + *1/*3 + *2/*3 + *2/*2 + *1/*5 + *2/*5 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 22274142 1184510108
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 losartan metabolism/PK yes Decreased metabolism indicated by decreased apparent oral clearance (CL/F; units = l/h) of losartan, decreased maximum plasma concentration (Cmax; units = (ng/ml)/(mg/kg) of the losartan metabolite E-3174, and increased elimination half-life (t1/2; units = h) of E-3174. E-3174 is the major active metabolite of losartan, and losartan is converted to E-3174 by the CYP2C9 enzyme. AUC and Cmax values were normalized by dose and body weight. CYP2C9 *1/*3 is associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1. 22735459 982028496
CYP2C9 CYP2C9*2 *2 phenprocoumon "dosage","toxicity" yes Patients carrying the CYP2C9 *2 allele were found to have an increased risk of severe overanticoagulation, and required a lower maintenance dose of phenprocoumon as compared to patients homozygous for the *1 allele. *2 allele carriers also had a lower chance to achieve a first period of stability within 6 months after starting therapy with phenprocoumon. CYP2C9 *2 is associated with decreased dose of phenprocoumon as compared to CYP2C9 *1. 15536456 1043737399
CYP2C9 rs1057910 C warfarin dosage yes This variant defines CYP2C9*3. Allele C is associated with decreased dose of warfarin as compared to allele A. 20072124 982037860
CYP2C9 rs56165452 C warfarin dosage yes in Turkish patients taking warfarin for >2 months. This variant defines CYP2C9*4. Homozygous variant genotype (*2/*2,*2/*3,and *3/*3) are grouped together, and heterozygous variant genotype (*1/*2,*1/*3,and *1/*4) are grouped together for analysis. Patients carrying one or two copies of CYP2C9 variant alleles are associated with lower dose of warfarin as compared to the homozygous wild type patients. Allele C is associated with decreased dose of warfarin as compared to allele T. 18542936 982036710
CYP2C9 rs1799853 T warfarin dosage yes Allele T is associated with decreased dose of warfarin as compared to allele C. 10961881 982033561
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 losartan metabolism/PK yes Subjects carrying the *3 allele showed significantly higher losartan/E3174 metabolic ratios as compared to patients with the *1 allele. This difference was also seen when subjects with the *3 allele were compared to subjects with the *2 allele, but to a lesser degree. This study determined that losartan would be a safe drug for use as a CYP2C9 activity probe. CYP2C9 *1/*3 is associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1. 15197523 1043880889
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*2 losartan efficacy yes Patients with secondary kidney diseases carrying CYP2C9 variant alleles (*2 or *3) showed increases in blood pressure (both systolic and diastolic) as compared to patients with the *1/*1 genotype. A nonsignificant trend towards improved urinary protein excretion was seen in patients with primary kidney diseases with the *1/*1 genotype as compared to patients carrying variant alleles (*2 or *3). CYP2C9 *1/*2 is associated with decreased response to losartan in people with Kidney Diseases as compared to CYP2C9 *1/*1. 19669737 1183490976
CYP2C9 rs1057910 CC fluvastatin metabolism/PK yes Area under concentration curve of 3R,5S fluvastatin was significantly different between genotypes in the order AA < AG < GG. Variant described as CYP2C9*3 (Ile359Leu) = rs1057910 allele C. Genotype CC is associated with decreased metabolism of fluvastatin in healthy individuals as compared to genotype AA. 12891229 982037386
CYP2C9 rs28371685 T warfarin dosage not stated using the extreme-discordant-phenotype (EDP) methodology. This variant defines CYP2C9*11. The EDP approach contrasts the most sensitive and the most resistant phenotype groups, which in the case of a quantitative trait such as the individual warfarin dose requirement correspond to the lower and upper ends of the dose distribution histogram. Allele T is associated with decreased dose of warfarin as compared to allele C. 19387626 982036973
CYP2C9 rs1799853 T warfarin dosage not stated using the extreme-discordant-phenotype (EDP) methodology. This variant defines CYP2C9*2. The EDP approach contrasts the most sensitive and the most resistant phenotype groups, which in the case of a quantitative trait such as the individual warfarin dose requirement correspond to the lower and upper ends of the dose distribution histogram. Allele T is associated with decreased dose of warfarin as compared to allele C. 19387626 982036901
CYP2C9 rs1799853 T fluvastatin metabolism/PK no CYP2C9 genotype had no effect on cholesterol or LDL cholesterol levels. Genotypes were grouped by carriers of 0, 1, or 2 CYP2C9*3 (rs1057910 allele C) alleles; CYP2C9*1/*1, *1/*2, *2/*2 vs CYP2C9*1/*3, *2/*3 vs CYP2C9*3/*3. CYP2C9*2 = rs1799853 allele T. Allele T is not associated with response to fluvastatin in healthy individuals as compared to allele C. 12891229 982037414
CYP2C9 CYP2C9*2 *2 phenprocoumon metabolism/PK yes Patients with increasing numbers of low activity alleles (*2 or *3) showed significantly decreasing ratios between S- and R-phenprocoumon total clearances. CYP2C9 *2 is associated with decreased metabolism of phenprocoumon in healthy individuals as compared to CYP2C9 *1. 15128047 1027521661
CYP2C9 rs56165452 C warfarin dosage not stated using the extreme-discordant-phenotype (EDP) methodology. This variant defines CYP2C9*4. The EDP approach contrasts the most sensitive and the most resistant phenotype groups, which in the case of a quantitative trait such as the individual warfarin dose requirement correspond to the lower and upper ends of the dose distribution histogram. Allele C is associated with decreased dose of warfarin as compared to allele T. 19387626 982036958
CYP2C9 rs1057910 CC fluvastatin metabolism/PK no CYP2C9 genotype had no effect on cholesterol or LDL cholesterol levels. Genotypes were grouped by carriers of 0, 1, or 2 CYP2C9*3 (rs1057910 allele C) alleles; CYP2C9*1/*1, *1/*2, *2/*2 vs CYP2C9*1/*3, *2/*3 vs CYP2C9*3/*3. Genotype CC is not associated with response to fluvastatin in healthy individuals as compared to genotype AA. 12891229 982037405
CYP2C9 rs1799853 T warfarin dosage yes in Turkish patients taking warfarin for >2 months. This variant defines CYP2C9*2. Homozygous variant genotype (*2/*2,*2/*3,and *3/*3) are grouped together, and heterozygous variant genotype (*1/*2,*1/*3,and *1/*4) are grouped together for analysis. Patients carrying one or two copies of CYP2C9 variant alleles are associated with lower dose of warfarin as compared to the homozygous wild type patients. Allele T is associated with decreased dose of warfarin as compared to allele C. 18542936 982036689
CYP2C9 rs28371686 G warfarin dosage not stated using the extreme-discordant-phenotype (EDP) methodology. This variant defines CYP2C9*5. The EDP approach contrasts the most sensitive and the most resistant phenotype groups, which in the case of a quantitative trait such as the individual warfarin dose requirement correspond to the lower and upper ends of the dose distribution histogram. Allele G is associated with decreased dose of warfarin as compared to allele C. 19387626 982036966
CYP2C9 rs1799853 T warfarin dosage not stated Allele T is associated with decreased dose of warfarin as compared to allele C. 11966680 982038144
CYP2C9 rs1057910 C warfarin dosage not stated using the extreme-discordant-phenotype (EDP) methodology. This variant defines CYP2C9*3. The EDP approach contrasts the most sensitive and the most resistant phenotype groups, which in the case of a quantitative trait such as the individual warfarin dose requirement correspond to the lower and upper ends of the dose distribution histogram. Allele C is associated with decreased dose of warfarin as compared to allele A. 19387626 982036874
CYP2C9 rs1799853 T warfarin "dosage","efficacy","toxicity" not stated Reduced function alleles CYP2C9*2 and CYP2C9*3 are pooled together for analysis. "Patients in the low-dose group were more likely to have difficulties at the time of induction of warfarin therapy (5.97 [2.26-15.82]) and have increased risk of major bleeding complications (rate ratio 3.68 [1.43-9.50]) when compared with randomly selected clinic controls." Allele T is associated with decreased dose of warfarin as compared to allele C. 10073515 982033292
CYP2C9 CYP2C9*1, CYP2C9*13 *1/*13 losartan metabolism/PK yes Decreased metabolism indicated by decreased apparent oral clearance (CL/F; units = l/h) of losartan, increased area under the plasma concentration time curve from time 0 to 8 hours (AUC0-8; units = nMxh/(mg/kg)) of losartan, increased AUC from time 0 to infinity (AUC0-infinity; units = nMxh/(mg/kg)) of losartan, decreased maximum plasma concentration (Cmax; units = (ng/ml)/(mg/kg) of the losartan metabolite E-3174, and increased elimination half-life (t1/2; units = h) of E-3174. E-3174 is the major active metabolite of losartan, and losartan is converted to E-3174 by the CYP2C9 enzyme. AUC and Cmax values were normalized by dose and body weight. CYP2C9 *1/*13 is associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1. 22735459 982028504
CYP2C9 CYP2C9*2 *2 phenprocoumon "dosage","metabolism/PK" yes Daily dose of phenprocoumon is not significantly associated with CYP2C9 genotype. Daily dose is negatively correlated with age. This study published an algorithm for daily dose that includes height, although height was not significant in univariate analysis. This haplotype is significantly associated with higher phenprocoumon concentration as compared to patients with the wildtype haplotype. CYP2C9 *2 is associated with decreased metabolism of phenprocoumon as compared to CYP2C9 *1. 21110013 982046660
CYP2C9 rs1799853 CT + TT fluvastatin metabolism/PK no PK parameters measured were not associated with the CYP2C9*2 carrier or wildtype genotypes. CYP2C9*2 was in strong LD with CYP2C8*3 (rs10509681 G, rs11572080 A). Genotypes CT + TT are not associated with metabolism of fluvastatin in healthy individuals as compared to genotype CC. 12891229 982037396
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 nateglinide metabolism/PK yes Only subjects with the GG genotype at SLCO1B1 position 388 (rs2306283) were recruited to eliminate any effect from this allele. Subjects were put into 4 groups. The reference group was CYP2C9 *1/*1 + SLCO1B1 521TT. The other three groups were: CYP2C9 *1/*3 + SLCO1B1 521TT, CYP2C9 *1/*1 + SLCO1B1 521TC/CC, and CYP2C9 *1/*3 + SLCO1B1 521TC. No subjects were found to be homozygous for the CYP2C9 *3 allele. Each group was found to have significantly higher AUCs and lower clearances when compared to the reference group. CYP2C9 *1/*3 is associated with decreased metabolism of nateglinide in healthy individuals as compared to CYP2C9 *1/*1. 22842957 982047452
CYP2C9 rs56165452 CT warfarin dosage yes This SNP defines CYP2C9*4. CYP2C9 *2,*3,*4,*5,*8 were grouped into three groups for testing: *1/*1 vs. *1/*2 + *1/*3 + *1/*4 + *1/*5 + *1/*8 vs *2/*2 + *2/*3 + *3/*3 + *5/*5. People having one or two variant alleles had lower dose requirements than people who were *1/*1. Genotype CT is associated with decreased dose of warfarin as compared to genotype TT. 21228733 982034970
CYP2C9 CYP2C9*2 *2 phenprocoumon dosage yes Patients carrying the *2 allele required significantly lower doses of phenprocoumon, but not acenocoumarol, as compared to patients homozygous for the wild-type allele (*1/*1). CYP2C9 *2 is associated with decreased dose of phenprocoumon as compared to CYP2C9 *1. 20020283 1043818092
CYP2C9 CYP2C9*3 *3 phenprocoumon dosage yes Presence of at least one *3 allele substantially decreased the maintenance dose of phenprocoumon as compared to patients homozygous for the wildtype allele (*1/*1). Age was also significantly negatively correlated with dose. CYP2C9 *3 is associated with decreased dose of phenprocoumon as compared to CYP2C9 *1. 20376629 1043818258
CYP2C9 CYP2C9*3 *3/*3 trimipramine metabolism/PK yes as compared to individuals with the reference diplotype (CYP2D6*1/*1, CYP2C9*1/*1 AND CYP2C19*1/*1). Elimination half-life of trimipramine was significantly higher in those with the *3/*3 diplotype. Clearance, plasma AUC and Cmax of trimipramine were not significantly different compared to the reference group. CYP2C9 *3/*3 is associated with decreased metabolism of trimipramine in healthy individuals. 14520122 1183621538
CYP2C9 CYP2C9*1, CYP2C9*30 *1/*30 losartan efficacy no Patients with the *1/*30 genotype showed a lack of decreases in systolic blood pressure as compared to patients with the *1/*1 genotype. Due to low sample size this difference was not statistically significant. CYP2C9 *1/*30 is associated with decreased response to losartan in people with Hypertension as compared to CYP2C9 *1/*1. 18971529 1183491069
CYP2C9 CYP2C9*1, CYP2C9*33 *1/*33 losartan efficacy no This SNP was presented as Arg132Gln. One patient was heterozygous for this variant, and showed a large decrease in systolic and diastolic blood pressure. Significance was not assessed due to low sample size. CYP2C9 *1/*33 is associated with increased response to losartan in people with Hypertension. 18971529 1183491076
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 losartan efficacy no Patients with the *1/*3 genotype showed similar decreases in systolic blood pressure as compared to patients with the *1/*1 genotype. CYP2C9 *1/*3 is not associated with decreased response to losartan in people with Hypertension as compared to CYP2C9 *1/*1. 18971529 1183491053
CYP2C9 CYP2C9*1, CYP2C9*2 *2 risperidone metabolism/PK no Variants (*2 or *3) in the CYP2C9 gene were not shown to have any effect on metabolism of risperidone or length of QTc. CYP2C9 *2 is not associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2C9 *1. 15260906 1183620420
CYP2C9 CYP2C9*1, CYP2C9*3 *3 risperidone metabolism/PK no Variants (*2 or *3) in the CYP2C9 gene were not shown to have any effect on metabolism of risperidone or length of QTc. CYP2C9 *3 is not associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2C9 *1. 15260906 1183620440
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 lornoxicam metabolism/PK yes As shown by increased AUC. CYP2C9 *1/*3 is associated with decreased metabolism of lornoxicam in healthy individuals as compared to CYP2C9 *1/*1. 15764711 1183703250
CYP2C9 CYP2C9*1, CYP2C9*3 *3 warfarin dosage yes *3 was associated with 38.1 %(95% CI 29.3 -45.7%) reduction in therapeutic dose (defined as the dose that gave an INR in the target therapeutic range after 7 consecutive days) per copy. CYP2C9 *3 is associated with decreased dose of warfarin in people with total knee or hip arthroplasty as compared to CYP2C9 *1. 17387222 1183699285
CYP2C9 CYP2C9*1, CYP2C9*10, CYP2C9*11, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6 *11 + *2 + *3 + *5 + *6 warfarin dosage yes Where (*2+*3+*5+*6+*11) are considered variant (*V), Average Daily maintenance dose for *1/*1 > *1/*V > *V/*V. *5,*6,*11 were only seen in African-Americans. This result was significant in European-Americans but not in African-Americans. CYP2C9 *11 + *2 + *3 + *5 + *6 is associated with decreased dose of warfarin as compared to CYP2C9 *1. 19802360 1183701419
CYP2C9 CYP2C9*1, CYP2C9*3 *3 warfarin dosage no This was a pilot study to compare traditional and PGx-guided dosing. CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1. 16160068 1183701565
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 + *3/*3 warfarin "dosage","efficacy" yes The mean dose of warfarin required to achieve target INR was 2.85 mg/day(SD 1.07) for *3 carriers vs 4.10 mg/day(SD 1.51) for "wild-type". CYP2C9 *1/*3 + *3/*3 is associated with decreased dose of warfarin in men as compared to CYP2C9 *1/*1. 10509530 1183700587
CYP2C9 rs1057910 AC + CC warfarin "dosage","efficacy" yes The mean dose of warfarin required to achieve target INR was 2.85 mg/day(SD 1.07) for *3 carriers(AC + CC) vs 4.10 mg/day(SD 1.51) for "wild-type" (AA). Genotypes AC + CC is associated with decreased dose of warfarin in men as compared to genotype AA. 10509530 1183700614
CYP2C9 rs1057910 CC celecoxib metabolism/PK yes Genotype CC was associated with a 10-fold higher AUC compared to genotype AA. One pediatric patient with CYP2C9*3/*3 genotype. Genotype CC is associated with decreased metabolism of celecoxib in children as compared to genotype AA. 16153401 1183690913
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 warfarin dosage yes Mean stable dose for *1/*3 patients was 1.72 +/- 0.55 mg/day. For *1/*1 patients, the mean stable dose was 3.09 +/- 1.14 mg/day. There was one *3/*3 patient, whose maintenance dose was 0.625 mg/day. CYP2C9 *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 19177029 1183699114
CYP2C9 CYP2C9*2 *2 warfarin dosage yes CYP2C9*2 and *3 explained 12% (P = 6.63 x 10(-34)) of the variation in warfarin dose. CYP2C9 *2 is associated with decreased dose of warfarin. 18574025 1183701108
CYP2C9 CYP2C9*1, CYP2C9*2 *2 warfarin dosage yes The study purpose was to develop a model for stable maintenance warfarin dose prediction. Most patients had a history of venous thromboembolism. *2 homozygous patients required a lower dose than *2 heterozygous patients, who required a lower dose than *1/*1 patients. CYP2C9 *2 is associated with decreased dose of warfarin in people with venous thromboembolism as compared to CYP2C9 *1. 20421126 1183701501
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 warfarin dosage yes Dose reduction was 33.7% (95% CI: 29.4 - 38.1%.) Only *2 and *3 were assayed; other genotypes were assumed to be *1. Since this was a meta-analysis, assay methods differed and were not specified. Studies were compared by normalizing doses to that of *1/*1. CYP2C9 *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 19031075 1183700096
CYP2C9 CYP2C9*1, CYP2C9*3 *3/*3 warfarin dosage yes Dose reduction was 78.1% (95% CI: 72.0 - 84.3%.) Only *2 and *3 were assayed; other genotypes were assumed to be *1. Since this was a meta-analysis, assay methods differed and were not specified. Studies were compared by normalizing doses to that of *1/*1. CYP2C9 *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 19031075 1183700123
CYP2C9 rs1799853 T celecoxib metabolism/PK no Allele T is not associated with celecoxib total clearance or AUC as compared to allele C. Allele T is not associated with clearance of celecoxib in healthy individuals as compared to allele C. 12893985 1183690922
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 warfarin efficacy yes Patients in this study were treated with low dose (1-2mg/day) warfarin. Patients with the *1/*3 genotype showed significantly higher S-warfarin concentrations and higher prothrombin times (INR) as compared to patients with the *1/*1 genotype. When CYP2C9 was analyzed in tandem with VKORC1, it was found that those patients with the highest number of variants (VKORC1 -1639 A alleles and CYP2C9 *3 alleles) had the highest INR measurements as compared to patients wildtype for both genes (-1639 GG VKORC1 genotype and CYP2C9 *1/*1) who had the lowest INR measurements. CYP2C9 *1/*3 is associated with increased response to warfarin as compared to CYP2C9 *1/*1. 22855348 1183690079
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *2 + *3 warfarin dosage yes This study endeavored to make a pharmacogenetic algorithm for warfarin dosing. This included two groups, a derivation group and a validation group. In the derivation group, subjects carrying one or two CYP2C9 variant alleles (*2 or *3) showed significantly decreased dose requirements for warfarin treatment as compared to patients with the wildtype genotype (*1/*1). This association was not statistically significant in the validation group. The algorithm used was: Square root of daily dose (mg) = 0.833 - 0.255 (0 for female, 1 for male gender) - 0.007 (age, years) + 0.011 (height, cm) + 0.005 (weight, kg) + 0.385 (smoking, 0=no, 1=yes) + 0.211 (vegetable intake, 0=no, 1=yes) + 0.119 (indication for OAT=VTE, 0=no, 1=yes) + 0.328 (diabetes, 0=no, 1=yes) - 0.458 (variant alleles of CYP2C9, 0, 1, or 2) - 0.571 (VKORC1 -1639 G>A, GG=0, GA=1, AA=2) + 0.025 (VKORC1 3730 G>A, GG=0, GA=1, AA=2). This algorithm underperformed most other published algorithms when determining dose for patients needing doses lower than 44 mg/week, but outperformed all other algorithms when determining dose for patients needing doses greater than or equal to 45 mg/week. CYP2C9 *2 + *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1. 22349464 1183697100
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *2/*3 warfarin dosage yes Dose reduction was 56.7% (95% CI: 49.1 - 64.3%.) Only *2 and *3 were assayed; other genotypes were assumed to be *1. Since this was a meta-analysis, assay methods differed and were not specified. Studies were compared by normalizing doses to that of *1/*1. CYP2C9 *2/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 19031075 1183700115
CYP2C9 CYP2C9*1, CYP2C9*13 *1/*13 lornoxicam metabolism/PK yes Oral clearance (CL/F). CYP2C9 *1/*13 is associated with decreased clearance of lornoxicam in healthy individuals as compared to CYP2C9 *1/*1. 15764711 1183703257
CYP2C9 CYP2C9*1, CYP2C9*13 *1/*13 lornoxicam metabolism/PK yes As shown by increased AUC. CYP2C9 *1/*13 is associated with decreased metabolism of lornoxicam in healthy individuals as compared to CYP2C9 *1/*1. 15764711 1183703264
CYP2C9 rs9332120 CC + CT losartan metabolism/PK no No association was found between this SNP and losartan metabolic ratios (losartan:E-3174). Genotypes CC + CT are not associated with metabolism of losartan in healthy individuals as compared to genotype TT. 22294058 1183697268
CYP2C9 CYP2C9*1, CYP2C9*2 *1/*2 warfarin dosage yes Dose reduction was 19.6% (95% CI: 17.4 - 21.9%.) Only *2 and *3 were assayed; other genotypes were assumed to be *1. Since this was a meta-analysis, assay methods differed and were not specified. Studies were compared by normalizing doses to that of *1/*1. CYP2C9 *1/*2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 19031075 1183700066
CYP2C9 CYP2C9*1, CYP2C9*2 *2/*2 warfarin dosage yes Dose reduction was 36.0% (95% CI: 29.9 - 42.0%.) Only *2 and *3 were assayed; other genotypes were assumed to be *1. Since this was a meta-analysis, assay methods differed and were not specified. Studies were compared by normalizing doses to that of *1/*1. CYP2C9 *2/*2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 19031075 1183700106
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 benzbromarone metabolism/PK yes Elimination half-life of the benzbromarone metabolite 6-hydroxybenzbromarone was significantly higher in individuals with the *1/*3 genotype. CYP2C9 *1/*3 is associated with decreased clearance of benzbromarone in healthy individuals as compared to CYP2C9 *1/*1. 20962433 1183680188
CYP2C9 CYP2C9*1, CYP2C9*3 *3/*3 meloxicam metabolism/PK yes CYP2C9 *3/*3 is associated with decreased clearance of meloxicam in healthy individuals as compared to CYP2C9 *1/*1 + *1/*3. 24322170 1183702049
CYP2C9 CYP2C9*1, CYP2C9*2 *1/*2 celecoxib metabolism/PK yes Subjects with the *1/*2 genotype had decreased maximum plasma concentration (Cmax; units = ng/ml), as compared to those with the *1/*1 genotype. However, no significant results for area under the curve from administration time to infinity (AUC; units = ng*h/ml), time to reach Cmax (Tmax; units = hours), elimination half-life (t1/2; units = hours), or clearance (units = ml/h*kg) were seen. CYP2C9 *1/*2 is associated with increased metabolism of celecoxib in healthy individuals as compared to CYP2C9 *1/*1. 23996211 1183680745
CYP2C9 CYP2C9*6 *6/*6 warfarin dosage no This was one case report. The patient was also reported to demonstrate impaired clearance of S-warfarin. CYP2C9 *6/*6 is associated with decreased dose of warfarin. 15094935 1183701586
CYP2C9 rs9332174 AG + GG losartan metabolism/PK no No association was found between this SNP and losartan metabolic ratios (losartan:E-3174). Genotypes AG + GG are not associated with metabolism of losartan in healthy individuals as compared to genotype AA. 22294058 1183697273
CYP2C9 CYP2C9*1, CYP2C9*2 *2 warfarin dosage no This was a pilot study to compare traditional and PGx-guided dosing. CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1. 16160068 1183701549
CYP2C9 CYP2C9*1, CYP2C9*2 *1/*2 warfarin dosage not stated Weekly maintenance doses were *1/*1: 38.6 mg; *1/*2: 28.5 mg. CYP2C9 *1/*2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 17989110 1183701311
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*2 + *2/*2 + *2/*3 warfarin dosage yes This study addressed the induction phase (defined here as the first 24 days of therapy). *2 and *3 were assayed. Patients with at least one *2 required a 17% lower mean daily dose compared to *1/*1 patients. CYP2C9 *1/*2 + *2/*2 + *2/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 15001971 1183700648
CYP2C9 CYP2C9*1, CYP2C9*2 *2 warfarin dosage yes Each CYP2C9*2 allele resulted in a 15% (11-19%) decrease in therapeutic dose on Day 4 or 5 of therapy. CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1. 20375999 1183700730
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 warfarin metabolism/PK yes Patients carrying a single variant allele (*2 or *3) had mean oral clearance of 2.96 +/- 1.67 ml/min, compared to 4.03 +/- 2.19 ml/min in *1/*1 patients (p < 0.02). Patients carrying two variant alleles had mean oral clearance of 0.98 +/- 0.41 ml/min, as compared to 4.03 +/- 2.19 ml/min for *1/*1 patients (p < 0.001). CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with decreased clearance of warfarin as compared to CYP2C9 *1/*1. 17851566 1183700824
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 warfarin dosage yes Patients carrying a single variant allele (*2 or *3) required 77% of the dose required by *1/*1 patients(p < 0.03). Patients carrying two variant alleles required 52% of the *1/*1 dose (p < 0.001). CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 17851566 1183700775
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 + *3/*3 warfarin dosage not stated Weekly maintenance doses were *1/*1: 37.3 mg; *1/*3 + *3/*3: 30.3 mg. CYP2C9 *1/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 17989110 1183701320
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 lornoxicam metabolism/PK yes Individuals with the CYP2C9 *1/*3 genotype had increased area under the plasma concentration-time curve (AUC) of lornoxicam and decreased AUC of 5'-hydroxylornoxicam as compared to those with the CYP2C9 *1/*1 genotype. CYP2C9 *1/*3 is associated with decreased metabolism of lornoxicam in healthy individuals as compared to CYP2C9 *1/*1. 16182270 1183703229
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 lornoxicam metabolism/PK yes Oral clearance (CL/F). CYP2C9 *1/*3 is associated with decreased clearance of lornoxicam in healthy individuals as compared to CYP2C9 *1/*1. 15764711 1183703238
CYP2C9 rs9332104 CC + CT losartan metabolism/PK no No association was found between this SNP and losartan metabolic ratios (losartan:E-3174). Genotypes CC + CT are not associated with metabolism of losartan in healthy individuals as compared to genotype TT. 22294058 1183697263
CYP2C9 CYP2C9*1, CYP2C9*2 *2 warfarin dosage yes *2 was associated with 17.4 %(95% CI 8.3-25.6%) reduction in therapeutic dose (defined as the dose that gave an INR in the target therapeutic range after 7 consecutive days) per copy. CYP2C9 *2 is associated with decreased dose of warfarin in people with total knee or hip arthroplasty as compared to CYP2C9 *1. 17387222 1183699310
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*3 + *2/*3 + *3/*3 warfarin dosage yes This study addressed the induction phase (defined here as the first 24 days of therapy). *2 and *3 were assayed. Patients with at least one *3 required a 40% lower mean daily dose compared to *1/*1 patients. CYP2C9 *1/*3 + *2/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 15001971 1183700669
CYP2C9 CYP2C9*1, CYP2C9*3 *3/*3 benzbromarone metabolism/PK not stated Peak plasma concentration, elimination half-life, and area under the concentrations vs time curve of benzbromarone were all higher in an individual with the *3/*3 genotype compared to individuals with the *1/*3 or *1/*1 genotypes. Oral clearance was lower. Only one individual with the *3/*3 genotype therefore no statistics were given. CYP2C9 *3/*3 is associated with decreased metabolism of benzbromarone in healthy individuals as compared to CYP2C9 *1/*1 + *1/*3. 20962433 1183680197
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 celecoxib metabolism/PK yes Subjects with the *1/*3 genotype had decreased clearance (units = ml/h*kg), increased maximum plasma concentration (Cmax; units = ng/ml) and increased area under the curve from administration time to infinity (AUC; units = ng*h/ml), as compared to those with the *1/*1 genotype. However, no significant results for time to reach Cmax (Tmax; units = hours) or elimination half-life (t1/2; units = hours) were seen. CYP2C9 *1/*3 is associated with decreased clearance of celecoxib in healthy individuals as compared to CYP2C9 *1/*1. 23996211 1183680709
CYP2C9 CYP2C9*1, CYP2C9*3 *3/*3 celecoxib metabolism/PK yes Subjects with the *3/*3 genotype had increased maximum plasma concentration (Cmax; units = ng/ml), as compared to those with the *1/*3 genotype. However, no significant results for time to reach Cmax (Tmax; units = hours) were seen. CYP2C9 *3/*3 is associated with decreased clearance of celecoxib in healthy individuals as compared to CYP2C9 *1/*3. 23996211 1183680733
CYP2C9 rs1057910 AC warfarin dosage yes Mean stable dose for AC (*1/*3) patients was 1.72 +/- 0.55 mg/day. For AA (*1/*1) patients, the mean stable dose was 3.09 +/- 1.14 mg/day. There was one CC (*3/*3) patient, whose maintenance dose was 0.625 mg/day. Genotype AC is associated with decreased dose of warfarin as compared to genotype AA. 19177029 1183699129
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*2 + *1/*3 + *2/*2 + *2/*3 warfarin dosage yes in a Southern Brazilian population of European ancestry. CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 21320153 1184510322
CYP2C9 rs1799853 T warfarin dosage yes T (*2) was associated with 17.4 %(95% CI 8.3-25.6%) reduction in therapeutic dose (defined as the dose that gave an INR in the target therapeutic range after 7 consecutive days) per copy. Allele T is associated with decreased dose of warfarin in people with total knee or hip arthroplasty as compared to allele C. 17387222 1183699325
CYP2C9 CYP2C9*1, CYP2C9*3 *3 dipyrone metabolism/PK no "CYP2C9 decreased function alleles was related to a near significant decrease of the formylated metabolite, as well as a significant decrease in the formylation ratio. Most of this effect is attributable to CYP2C9*3, whereas the presence of CYP2C9*2 was related to a weaker effect." CYP2C8 polymorphisms did not show any influence on recoveries of metamizole metabolites or on metabolic ratios. CYP2C9 *3 is associated with decreased metabolism of dipyrone in healthy individuals as compared to CYP2C9 *1/*1. 25241292 1451138980
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *2 + *3 warfarin dosage yes Patients with the *2 or *3 alleles showed significantly lower doses (17% or 32%, respectively) of warfarin as compared to patients with the wildtype genotype (*1/*1). When studied together with VKORC1 1639G/A, patients carrying variants in both genes needed between 34.8% and 84% of the dose needed for patients wildtype for both genes. CYP2C9 *2 + *3 are associated with decreased dose of warfarin in people with Cardiovascular Diseases as compared to CYP2C9 *1. 23990957 1183697679
CYP2C9 CYP2C9*1, CYP2C9*3 *3 warfarin dosage yes Each CYP2C9*3 allele resulted in a 28% (23-32%) decrease in therapeutic dose on Day 4 or 5 of therapy. CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1. 20375999 1183700748
CYP2C9 CYP2C9*1, CYP2C9*8 *8/*8 warfarin dosage yes An African-American male previously typed as *1/*1 but whose therapeutic warfarin dose was low (14.4 mg/wk) was sequenced and found to be *8/*8. Out of 600 African American alleles genotyped, the frequency of *8 was 0.047 . CYP2C9 *8/*8 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 19663669 1183700910
CYP2C9 rs1799853 T indomethacin efficacy no among neonates with patent ductus arteriosus (PDA). Allele T is associated with increased response to indomethacin as compared to allele C. 28609430 1451140100
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 warfarin dosage yes CYP2C9 *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 22075505 1184510172
CYP2C9 CYP2C9*1 *1/*1 warfarin "dosage","metabolism/PK" not stated Only one participant had the *2/*3 genotype CYP2C9 *1/*1 is associated with increased dose of warfarin in children as compared to CYP2C9 *2/*3. 22010099 982047415
CYP2C9 CYP2C9*1, CYP2C9*2 *1/*2 warfarin dosage no CYP2C9 *1/*2 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1. 24474498 1184472866
CYP2C9 CYP2C9*1, CYP2C9*12 *1/*12 warfarin dosage not stated CYP2C9 *1/*12 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 23688605 1184483284
CYP2C9 CYP2C9*1 *1/*1 warfarin "dosage","metabolism/PK" no CYP2C9 *1/*1 is associated with increased dose of warfarin in children as compared to CYP2C9 *1/*2. 22010099 982047403
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 warfarin dosage yes CYP2C9 *1/*3 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1. 24474498 1184472857
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5 *3 + *5 + *2 + *1 warfarin dosage yes Neither the addition of race, number of concurrent medications nor the number of concurrent medications interacting with warfarin enhanced algorithm performance. Similarly, consideration of CYP4F2, CALU or GGCX variant genotypes did not improve algorithms. CYP2C9 *3 + *5 + *2 + *1 is associated with dose of warfarin. 20128861 1184472455
CYP2C9 CYP2C9*1, CYP2C9*2 *2 warfarin dosage yes with an approximate decrease of daily dose of 0.82mg. CYP2C9 *2 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1. 25001883 1184473587
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 acenocoumarol dosage no CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is not associated with dose of acenocoumarol as compared to CYP2C9 *1/*1. 25042728 1184511592
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 warfarin dosage yes CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 25042728 1184511561
CYP2C9 rs1057910 AC warfarin dosage yes in Korean patients with prosthetic cardiac valves. Genotype AC is associated with decreased dose of warfarin as compared to genotype AA. 25026456 1184511620
CYP2C9 CYP2C9*1, CYP2C9*2 *1/*2 warfarin dosage yes Genetic variants in CYP2C9 contributed to 12.4% of the variation in warfarin dose. CYP2C9 *1/*2 is associated with increased dose of warfarin as compared to CYP2C9 *1/*1. 24019055 1184469338
CYP2C9 CYP2C9*1, CYP2C9*8 *1/*8 diclofenac metabolism/PK yes Healthy individuals with the *1/*8 genotype had a higher diclofenac/4'-OH diclofenac metabolite ratio, as compared to those with the *1/*1 genotype. No significant results were seen when considering the diclofenac/3'-OH metabolite ratio, or the diclofenac/5'-OH metabolite ratio. CYP2C9 *1/*8 is associated with decreased metabolism of diclofenac in healthy individuals as compared to CYP2C9 *1/*1. 23959274 1184510815
CYP2C9 CYP2C9*1, CYP2C9*11, CYP2C9*12, CYP2C9*2, CYP2C9*3, CYP2C9*6 *1/*3 + *2/*2 + *2/*3 + *2/*11 + *2/*12 + *3/*11 + *3/*12 + *6/*11 + *3/*3 prasugrel efficacy no Plasma concentrations of active drug metabolite and platelet inhibition in response to prasugrel were assessed in the healhy subject cohort, and clinical outcome(risk of cardiovascular death, myocardial infarction or stroke) was assessed in the large cohort of patients with acute coronary syndromes. CYP2C9 *1/*3 + *2/*2 + *2/*3 + *2/*11 + *2/*12 + *3/*11 + *3/*12 + *6/*11 + *3/*3 (assigned as poor metabolizers and intermediate metabolizers phenotype) is not associated with response to prasugrel in healthy individuals as compared to CYP2C9 *1/*1 + *1/*2 + *1/*11 + *1/*12 (assigned as normal metabolizer phenotype) . 19414633 1184470543
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *2/*3 warfarin "dosage","efficacy" not stated A model was created to predict maintenance doses for children of different ages, all with a baseline INR of 1 and a target INR of 2.5, based on longitudinal data from children taking warfarin. Due to the nature of the model, the quantitative CYP2C9 allele effects on clearance were assumed to be the same as for adults - n=2 children had the *2/*3 genotype in the data cohort. CYP2C9 genotype, VKORC1 genotype, bodyweight, age, baseline INR, target INR and time since initiation of therapy were all found to be significant causes of warfarin dose variability in children. This association is based on a table presenting results from the model predicting warfarin dose for children of 2, 8 and 14 years old with different rs9923231 genotype and CYP2C9 genotype presented in the paper. CYP2C9*2 was defined as rs1799853 and *3 as rs1057910. CYP2C9 *2/*3 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1/*1. 24330000 1184654374
CYP2C9 CYP2C9*3 *3 warfarin dosage yes This variant was associated with requiring a lower warfarin dose. Linear regression and polynomial regression was used to calculate the contribution of each variable towards therapeutic dose of warfarin, prior to the development of pharmacogenetic algorithms. CYP2C9 *3 is associated with decreased dose of warfarin. 25084205 1184748897
CYP2C9 CYP2C9*1, CYP2C9*2 *1/*1 + *1/*2 propofol metabolism/PK yes In individuals undergoing elective surgery (e.g. minor orthopaedic or plastic surgery) under general anaesthesia. Concentrations at the time of loss-of-consciousness. Authors note that only two patients had the *2/*2 genotype. CYP2C9 *1/*1 + *1/*2 is associated with decreased concentrations of propofol in people with as compared to CYP2C9 *2/*2. 24891132 1184747909
CYP2C9 rs9332127 G warfarin dosage no Samples, genotypes and INRs from a cohort of 551 patients were used to derive an algorithm which was used to predict daily warfarin maintenance dose in a second cohort of 236 patients. Note: the authors state that "SNPs were tested for deviations from HWE using the chi-squared test, and for their association with the warfarin dose by Spearman correlation analysis using a *co-dominant* model." Allele G is not associated with dose of warfarin in people with heart valve replacement as compared to allele C. 25126975 1184757013
CYP2C9 CYP2C9*1, CYP2C9*3 *3 acenocoumarol dosage yes in both the initiation and maintenance phase of anticoagulation. CYP2C9 *3 is associated with decreased dose of acenocoumarol in people with Thrombosis of cerebral veins as compared to CYP2C9 *1. 24530212 1444705951
CYP2C9 CYP2C9*1, CYP2C9*2 *1/*2 + *2/*2 acenocoumarol dosage not stated The decrease varied from 9% in the first week (1.3 mg) to 17% in the seventh week (3.13 mg). CYP2C9 *1/*2 + *2/*2 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1. 18781852 1184996788
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 + *3/*3 acenocoumarol dosage not stated Carriers of at least one CYP2C9*3 variant allele decreased the weekly dose to a greater degree than CYP2C9*2. They had 22% decrease in dose in the first week of therapy (3.1 mg) and 25% decrease in the seventh week (4.8 mg) as compared to the wild type. CYP2C9 *1/*3 + *3/*3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1. 18781852 1184996801
CYP2C9 CYP2C9*1, CYP2C9*3 *3 acenocoumarol dosage yes The CYP2C9*2, *3 and VKORC1 rs9923231 are analyzed together. Patients carrying any of the variant alleles was 34% among those receiving a low dose of =20 mg/wk while it was 13.8 per cent in those receiving >20 mg/wk (P=0.014). CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1. 23481074 1444705544
CYP2C9 CYP2C9*1, CYP2C9*2 *2 acenocoumarol dosage yes The CYP2C9*2, *3 and VKORC1 rs9923231 are analyzed together. Patients carrying any of the variant alleles was 34% among those receiving a low dose of =20 mg/wk while it was 13.8 per cent in those receiving >20 mg/wk (P=0.014). CYP2C9 *2 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1. 23481074 1444705555
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *2 + *3 acenocoumarol dosage not stated in a spanish population. CYP2C9 *2 + *3 are not associated with dose of acenocoumarol as compared to CYP2C9 *1/*1. 12123234 1444707494
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 + *3/*3 acenocoumarol dosage yes CYP2C9 *1/*3 + *3/*3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1. 19277427 1444706944
CYP2C9 CYP2C9*1, CYP2C9*2 *1/*2 + *2/*2 acenocoumarol dosage no CYP2C9 *1/*2 + *2/*2 are not associated with decreased dose of acenocoumarol. 19277427 1444706957
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*3 + *2/*3 + *2/*2 acenocoumarol dosage yes in Bulgarian patients. CYP2C9 *1/*3 + *2/*3 + *2/*2 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1. 18021343 1444707113
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *3 + *2 acenocoumarol dosage not stated The effect of the 2C9*2 allele on the acenocoumarol requirement was much smaller than the effect exerted by the 2C9*3 allele. CYP2C9 *3 + *2 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1. 12010835 1444707507
CYP2C9 CYP2C9*1, CYP2C9*2 *2 warfarin dosage yes This is using Classification I. It divided the individuals into three dose ranges: <=21 mg, 21–49 mg, and >= 49 mg/week. CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1. 25312789 1444666225
CYP2C9 CYP2C9*1, CYP2C9*2 *2 acenocoumarol dosage yes in both the initiation and maintenance phase of anticoagulation. CYP2C9 *2 is associated with decreased dose of acenocoumarol in people with Thrombosis of cerebral veins as compared to CYP2C9 *1. 24530212 1444705930
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*2 + *1/*3 + *2/*2 + *3/*3 acenocoumarol dosage yes CYP2C9 *1/*2 + *1/*3 + *2/*2 + *3/*3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1. 16699986 1444707144
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*2 + *2/*2 + *1/*3 + *3/*3 phenprocoumon dosage not stated Mean phenprocoumon dosage per week to achieve therapeutic anticoagulation was lower in patients with the VKORC1 polymorphism -1639G > A (3730G > A) or the CYP2C9 polymorphisms. CYP2C9 *1/*2 + *2/*2 + *1/*3 + *3/*3 are associated with decreased dose of phenprocoumon as compared to CYP2C9 *1/*1. 18629445 1444707861
CYP2C9 CYP2C9*1, CYP2C9*3 *3 4-hydroxytamoxifen metabolism/PK no Patients (pre- (83%) and postmenopausal (17%)) with ER and/or PR positive breast tumors, which received 20 mg tamoxifen daily. Patients taking CYP2D6 inhibitors were excluded. DNA extracted from blood. CYP2C9 *3 is not associated with concentrations of 4-hydroxytamoxifen, endoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2C9 *1. 21480951 1444710945
CYP2C9 CYP2C9*1, CYP2C9*59 *1/*59 warfarin dosage not stated The patient only required half of the oral amount of warfarin that is commonly used for most Chinese individuals. CYP2C9 *1/*59 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 25994031 1445117476
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*3 + *2/*3 + *3/*3 + *2/*2 warfarin dosage yes CYP2C9 *1/*3 + *2/*3 + *3/*3 + *2/*2 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 14676821 1447024584
CYP2C9 CYP2C9*1, CYP2C9*11, CYP2C9*5, CYP2C9*6 *5 + *6 + *11 warfarin dosage yes in African Americans. CYP2C9 *5 + *6 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 26024874 1445296737
CYP2C9 rs1934969 AT + TT phenytoin metabolism/PK yes Patients with the AT and TT genotypes had, on average, a 1.7X higher dose-corrected phenytoin concentration as compared to patients with the AA genotype. Multivariate analysis, adjusted for sex and age. The frequency of the T allele was also higher in the supratherapeutic group (phenytoin plasma concentrations <20 ug/ml) as compared to the subtherapeutic group (<10 ug/ml; p=0.05). Genotypes AT + TT is associated with increased dose-adjusted trough concentrations of phenytoin in people with Epilepsy as compared to genotype AA. 26122019 1445379985
CYP2C9 CYP2C9*1, CYP2C9*8 *1/*8 + *8/*8 warfarin metabolism/PK yes in African Americans. Patients with CYP2C9*8 had a 30% reduction in S-warfarin clearance as compared to patients with *1/*1 genotype. CYP2C9*8, but not CYP2C9*2/*3, and body surface area (BSA)/body weight were determinants of S-warfarin clearance (CL[S]) in African–American. Dosing algorithm that excludes African-specific variant(s) may lead to prediction errors in African Americans. CYP2C9 *1/*8 + *8/*8 are associated with decreased clearance of warfarin as compared to CYP2C9 *1/*1. 25712185 1444695840
CYP2C9 CYP2C9*1, CYP2C9*2 *1/*2 + *2/*2 warfarin dosage yes only in European Americans, but not African Americans. (20.6% vs 3.0% dose reduction per variant allele, interaction p value<0.001) CYP2C9 *1/*2 + *2/*2 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 26024874 1445296627
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *2 + *3 4-hydroxytamoxifen metabolism/PK yes Tamoxifen arm (20mg/day) of an ongoing German prospective observational multicenter breast cancer trial (IKP211) with the following inclusion primary breast cancer (pT1–4; N1–2; M0) were postmenopausal status, positive ER status, past administration of an adequate adjuvant chemotherapy, and past or concomitant radiation therapy. Plasma samples at baseline, 6 months, and 1 year after the commencement of tamoxifen treatment. DNA was extracted from blood. CYP2C9 *2 + *3 (assigned as poor metabolizers phenotype) are associated with decreased concentrations of 4-hydroxytamoxifen and endoxifen in women with Breast Neoplasms as compared to CYP2C9 *1/*1 (assigned as normal metabolizers phenotype) . 21451508 1445401027
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 + *3/*3 warfarin dosage yes in both European Americans and African Americans. The dose reduction per variant allele was comparable among European Americans (34.6% vs 34.4%, interaction P value=0.98) vs. African Americans. CYP2C9 *1/*3 + *3/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 26024874 1445296671
CYP2C9 rs7089580 AT warfarin dosage yes Genotype AT is associated with increased dose of warfarin as compared to genotype AA. 25499099 1444608095
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*3 + *3/*3 acenocoumarol dosage yes CYP2C9 *1/*3 + *3/*3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1 + *1/*2 + *2/*2. 24956252 1444705825
CYP2C9 CYP2C9*1, CYP2C9*11, CYP2C9*5, CYP2C9*8, CYP2C9*9 *9/*11 + *5/*8 acenocoumarol metabolism/PK no These subjects with the CYP2C9*9/*11 and CYP2C9*5/*8 genotypes appeared to have reduced enzyme activity and increased plasma concentrations of S-acenocoumarol at 8h. However, this didn't reach statistical significance. CYP2C9 *9/*11 + *5/*8 are associated with decreased metabolism of acenocoumarol in healthy individuals as compared to CYP2C9 *1/*1. 21811894 1444706610
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*2 + *2/*2 + *2/*3 + *1/*3 + *3/*3 phenprocoumon dosage no CYP2C9 affected the phenprocoumon concentration, but not the dose requirements. CYP2C9 *1/*2 + *2/*2 + *2/*3 + *1/*3 + *3/*3 are not associated with decreased dose of phenprocoumon as compared to CYP2C9 *1/*1. 21110013 1444708196
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*2 + *2/*2 + *1/*3 + *3/*3 warfarin dosage yes in North-Italian patients. CYP2C9 *1/*2 + *2/*2 + *1/*3 + *3/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 14521618 1444707383
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*3 + *2/*3 acenocoumarol metabolism/PK yes CYP2C9 *1/*3 + *2/*3 are associated with decreased clearance of acenocoumarol as compared to CYP2C9 *1/*1. 12844136 1444707442
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*2 + *2/*2 + *1/*3 + *2/*3 phenprocoumon dosage no CYP2C9 *1/*2 + *2/*2 + *1/*3 + *2/*3 are not associated with decreased dose of phenprocoumon as compared to CYP2C9 *1/*1. 23423913 1444707660
CYP2C9 CYP2C9*1, CYP2C9*2 *1/*2 + *2/*2 phenprocoumon dosage no No statistically significant correlation was found between CYP2C9 genotypes and phenprocoumon dosage during initiation of phenprocoumon therapy.The maintenance dose in patients on long-term treatment tended to be slightly lower for carriers of variant alleles than for wild-type genotype for all analyzed CYP2C9 gene loci, but this difference was also not statistically significant. Instead, obesity appears to directly correspond to the amount of phenprocoumon required during initiation of therapy. CYP2C9 *1/*2 + *2/*2 are not associated with decreased dose of phenprocoumon as compared to CYP2C9 *1/*1. 16847664 1444707881
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 + *3/*3 phenprocoumon dosage no No statistically significant correlation was found between CYP2C9 genotypes and phenprocoumon dosage during initiation of phenprocoumon therapy.The maintenance dose in patients on long-term treatment tended to be slightly lower for carriers of variant alleles than for wild-type genotype for all analyzed CYP2C9 gene loci, but this difference was also not statistically significant. Instead, obesity appears to directly correspond to the amount of phenprocoumon required during initiation of therapy. CYP2C9 *1/*3 + *3/*3 are not associated with decreased dose of phenprocoumon as compared to CYP2C9 *1/*1. 16847664 1444707894
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3 phenprocoumon metabolism/PK yes CYP2C9 *1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3 are associated with decreased metabolism of phenprocoumon in healthy individuals as compared to CYP2C9 *1/*1. 15742978 1444707906
CYP2C9 rs1934969 AA losartan metabolism/PK yes The mean losartan metabolic ratio (losartan:E3174 metabolite log10) was higher in patients with the AA genotype compared to patients with the TT genotype. Note that only 8 individuals had the TT genotype, compared to 95 with the AA genotype. Genotype AA is associated with decreased metabolism of losartan in healthy individuals as compared to genotype TT. 25303293 1185234889
CYP2C9 CYP2C9*1, CYP2C9*3 *3 warfarin dosage yes This is using Classification I. It divided the individuals into three dose ranges: <=21 mg, 21–49 mg, and >= 49 mg/week. CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1. 25312789 1444608072
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *2 + *3 endoxifen metabolism/PK no No significant difference in the mean plasma concentrations of tamoxifen, endoxifen, 4-Hydroxytamoxifen, and N-desmethyltamoxifen. after 4 months of tamoxifen therapy (20mg/day). Pre- and postmenopausal women with newly diagnosed breast cancer who were starting tamoxifen as standard adjuvant therapy are included; participants were allowed to take vitamin E, SSRIs, or herbal remedies. Genotyped for *2 and *3. CYP2C9 *2 + *3 are not associated with concentrations of endoxifen or tamoxifen in women with Breast Neoplasms as compared to CYP2C9 *1/*1. 15632378 1444708893
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*2 + *2/*2 + *1/*3 + *3/*3 + *2/*3 acenocoumarol dosage yes The acenocoumarol dosage in mg/week had to be significantly titrated downward in association with an increasing number of CYP2C9 variant alleles (-1.8, 95% CI -2.1 to -1.5, Pvalue for trend <0.0001) . CYP2C9 *1/*2 + *2/*2 + *1/*3 + *3/*3 + *2/*3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1. 19225451 1444706981
CYP2C9 rs1799853 T sulfonamides, urea derivatives efficacy no Allele T is not associated with response to sulfonamides, urea derivatives in people with Diabetes Mellitus as compared to allele C. 29681852 1449310654
CYP2C9 CYP2C9*1, CYP2C9*3 *3 valproic acid metabolism/PK no Clearance here refers to apparent oral clearance as assayed by serum concentration of valproic acid (VPA) (micrograms/ml). The authors used NONEM to assess serum concentration of VPA. CYP2C9 *3 is not associated with clearance of valproic acid in people with Epilepsy as compared to CYP2C9 *1. 25372290 1444608478
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 acenocoumarol metabolism/PK not stated The paper found that the presence of even one copy of CYP2C9*3 reduced the metabolic clearance of S -acenocoumarol. As a result the first-pass effect of elimination is abolished and the maintenance time is increased. CYP2C9 *1/*3 is associated with decreased clearance of acenocoumarol as compared to CYP2C9 *1/*1. 11557918 1444707532
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*3 + *2/*3 warfarin dosage yes CYP2C9 *1/*3 + *2/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 20339978 1447586737
CYP2C9 CYP2C9*1, CYP2C9*2 *1/*2 warfarin dosage no CYP2C9 *1/*2 is not associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 20339978 1447586752
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*8 *2 + *3 + *8 warfarin dosage yes The authors aimed to develop an admixture-adjusted (genetic ancestry) PGx dosing algorithm for warfarin in Caribbean Hispanics from Puerto Rico. [Algorithm R sq.=0.70, MAE = 0.72 mg/day]. When externally validated with 55 individuals from an independent cohort the novel algorithm predicted 58% of the warfarin dose variance [MAE = 0.89 mg/day, 24% mean bias]. Please note: the derivation cohort was 99% male and "variables were included in final lin. reg model if p<0.05 or if association with daily warfarin dose was marginally significant 0.05 = p = 0.20 with strong biological plausability". CYP2C9 *2 + *3 + *8 are associated with decreased dose of warfarin as compared to CYP2C9 *1. 26745506 1447682605
CYP2C9 CYP2C9*1, CYP2C9*2 *2 warfarin dosage yes CYPC9*2 variant 3.6 mg, wild type 4.0mg. CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 22571356 1447223171
CYP2C9 CYP2C9*1, CYP2C9*3 *3 warfarin dosage no CYPC9*3 variant 4.2 mg, wild type 4.0mg. CYP2C9 *3 is not associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 22571356 1447223182
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *2 + *3 warfarin dosage yes CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 19074728 1447573274
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*1 flurbiprofen metabolism/PK yes This genotype was associated with increased CL/F. CYP2C9 *1/*1 is associated with increased clearance of flurbiprofen in healthy individuals as compared to CYP2C9 *1/*3. 25712887 1444828107
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *2 + *3 warfarin dosage not stated CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 20386359 1447586674
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 flurbiprofen metabolism/PK yes This genotype was associated with increased half-life and AUC. CYP2C9 *1/*3 is associated with increased concentrations of flurbiprofen in healthy individuals as compared to CYP2C9 *1/*1. 25712887 1444828093
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3 warfarin dosage yes CYP2C9 *1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 19794411 1447520262
CYP2C9 CYP2C9*1, CYP2C9*11, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6 *2 + *3 + *5 + *6 + *11 warfarin dosage yes in European Americans. CYP2C9 *2 + *3 + *5 + *6 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 18466099 1447519652
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *2 + *3 warfarin dosage not stated CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 23602689 1447519344
CYP2C9 CYP2C9*1, CYP2C9*2 *2 warfarin dosage yes Mean difference in daily warfarin dose for CYP2C9*2 carriers vs wild type, the reduction was 0.85 mg (0.60-1.11 mg), a 17% reduction. CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 15714076 1447519445
CYP2C9 CYP2C9*1, CYP2C9*3 *3 warfarin dosage yes Mean difference in daily warfarin dose for CYP2C9*3 carriers vs wild type, the reduction was 1.92 mg (1.37-2.47 mg), a 37% reduction. CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 15714076 1447519456
CYP2C9 rs72558187 CT irbesartan metabolism/PK yes Subjects were healthy Korean males between the ages of 20-24. Each subject received a 150-mg oral dose of irbesartan after overnight fast. Subjects were maintained in the fasting state for 4 h after administration of the drug. Venous blood samples (10 mL) were obtained before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, and 36 h after irbesartan administration. The PK parameters of irbesartan were estimated using non-compartmental methods. In the study the rs72558187 C is referred to as the CYP2C9 *13 allele. Differences in PK parameters are in reference to CYP2C9 *1/*13 (rs72558187 CT) vs CYP2C9 *1/*1 (rs72558187 TT). Genotype CT is associated with decreased metabolism of irbesartan in healthy individuals as compared to genotype TT. 21842338 1447947823
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *2 + *3 warfarin dosage yes in Caucasians, but not in African american patients. CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 17324110 1447520623
CYP2C9 rs2860905 A warfarin dosage yes Allele A is associated with decreased dose of warfarin as compared to allele G. 19752777 1447519938
CYP2C9 CYP2C9 poor metabolizer *2 + *3 cyclophosphamide efficacy no this was a trend in the orally treated subset but not seen in the subset of just Wegener granulomatosis (granulomatosis with polyangiitis) patients. Odds ratios for likelihood of refractory disease. Poor metabolizers were patients with *2 and *3 alleles. Genotypes *2 + *3 (assigned as poor metabolizer phenotype) is associated with increased response to cyclophosphamide in people with Vasculitis and Wegener Granulomatosis as compared to genotype *1/*1. 26894931 1447949358
CYP2C9 CYP2C9*1, CYP2C9*3 *3 warfarin dosage no in Thai patients. CYP2C9 *3 is not associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 26219158 1446848557
CYP2C9 rs1057910 AC warfarin dosage yes Average mean stable warfarin dose was 5.48+/-1.90 mg/day. Current age, age at operation, atrial fibrillation were all significantly associated with warfarin dose. Genotype AC is associated with decreased dose of warfarin as compared to genotype AA. 26257249 1446765922
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*3 + *2/*3 + *3/*3 warfarin dosage yes Patients with the CYP2C9*2 allele (CYP2C9*1*2 or *2*2 genotype) showed no significant difference in the mean dose (5.2±2.4 mg) when compared to CYP2C9*1*1 patients (5.3±2.1 mg), whereas those with at least one copy of the CYP2C9*3 allele (CYP2C9*1*3, *2*3 ,or *3*3 genotype) required a daily dose of 3.1±1.8 mg, corresponding to a 37% reduction, on average, of the standard warfarin dose. CYP2C9 *1/*3 + *2/*3 + *3/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 17955230 1447148309
CYP2C9 CYP2C9*1, CYP2C9*2 *1/*2 + *2/*2 warfarin dosage no Patients with the CYP2C9*2 allele (CYP2C9*1*2 or *2*2 genotype) showed no significant difference in the mean dose (5.2±2.4 mg) when compared to CYP2C9*1*1 patients (5.3±2.1 mg), whereas those with at least one copy of the CYP2C9*3 allele (CYP2C9*1*3, *2*3 ,or *3*3 genotype) required a daily dose of 3.1±1.8 mg, corresponding to a 37% reduction, on average, of the standard warfarin dose. CYP2C9 *1/*2 + *2/*2 are not associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 17955230 1447148324
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 warfarin dosage yes CYP2C9 *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 18570163 1447519494
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 warfarin dosage yes Mean maintenance dose varied significantly among the 6 genotype groups (*1/*1 [n = 127], *1/*2 [n = 28], *1/*3 [n = 18], *2/*2 [n = 4], *2/*3 [n = 3], *3/*3 [n = 5]) (by Kruskall-Wallis test, chi(2)(5) = 37.348; P<.001) CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*2. 11926893 1447519521
CYP2C9 CYP2C9*1, CYP2C9*3 *3 clopidogrel efficacy no All patients were on double-antiplatelet therapy (aspirin, 125 mg/day; clopidogrel, 75 mg/day) at least 7 days before carotid artery stenting. CYP2C9 *3 is not associated with response to clopidogrel in people with Carotid Artery Diseases as compared to CYP2C9 *1. 26526111 1448115838
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 + *3/*3 warfarin dosage not stated The study evaluated the International Warfarin Pharmacogenetics Consortium (IWPC) algorithm against a clinical algorithm for warfarin dose requirements in Japanese patients. This variant was included in the IWPC algorithm. CYP2C9 *1/*3 + *3/*3 are associated with dose of warfarin. 20339191 1448267890
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 warfarin dosage yes The study generated a warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients. This variant was significantly associated with stable warfarin dose in stepwise multivariate analysis, and was included in the algorithm. CYP2C9 *1/*3 is associated with dose of warfarin. 20585834 1448267915
CYP2C9 CYP2C9*3 *3 warfarin dosage not stated This study undertook the development of a warfarin pharmacogenetic dosing algorithm and then compared it against other dosing algorithms. This variant was included in the algorithm. However, note that there was no significant difference in stable warfarin dose between patients with the *1/*1 genotype (3.8+/1.4 mg/day) and the *1/*3 genotype (2.6+/-0.5 mg/day); only 4 patients carried the *3 allele. CYP2C9 *3 is associated with dose of warfarin in people with Stroke. 26996562 1448267948
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 warfarin dosage yes The mean warfarin daily dose required was significantly lower in patients with the *1/*3 genotype (1.93+/-1.14 mg/day) as compared to those with the *1/*1 genotype (2.72+/-0.89 mg/day). Additionally, this study developed a pharmacogenetic algorithm to predict daily stable dose of warfarin in Chinese patients; this variant was present in the algorithm. CYP2C9 *1/*3 is associated with decreased dose of warfarin in people with Atrial Fibrillation as compared to CYP2C9 *1/*1. 22534826 1448268043
CYP2C9 CYP2C9*2, CYP2C9*3 *2 + *3 warfarin dosage not stated This study assessed the impact of using genotype-guided dosing on anticoagulation visits in adults taking warfarin. Genotype-guided dosing did NOT improve number of anticoagulation visits or time in therapeutic range as compared to clinical only dosing. However, the algorithm used by this study to determine warfarin dose included these variants. CYP2C9 *2 + *3 are associated with dose of warfarin. 24088130 1448268118
CYP2C9 CYP2C9*2, CYP2C9*3 *2 + *3 warfarin dosage not stated Study undertaking a randomized trial of genotype-guided dosing of warfarin. The algorithms that the study used to calculate loading dose and dose revision on day 4 or 5 of treatment included these variants. CYP2C9 *2 + *3 is associated with dose of warfarin in people with Atrial Fibrillation and venous thromboembolism. 24251363 1448268948
CYP2C9 CYP2C9*1, CYP2C9*2 *1/*2 warfarin dosage yes Maintenance warfarin doses in pediatric patients with CYP2C9 *1/*2 genotype were 15% lower than doses in patients with the wild type allele (CYP2C9 *1/*1). CYP2C9 *1/*2 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1. 27661060 1448276095
CYP2C9 rs4917639 C warfarin dosage yes Samples, genotypes and INRs from a cohort of 551 patients were used to derive an algorithm which was used to predict daily warfarin maintenance dose in a second cohort of 236 patients. Note: the authors state that "SNPs were tested for deviations from HWE using the chi-squared test, and for their association with the warfarin dose by Spearman correlation analysis using a *co-dominant* model." rs4917639 only remained significantly associated with warfarin maintenance dose in the first cohort but did not remain significant in the multivariate analysis. Allele C is associated with decreased dose of warfarin in people with heart valve replacement as compared to allele A. 25126975 1184756122
CYP2C9 rs1057910 A warfarin dosage not stated This variant annotation is part of a dosing algorithm table based on 8 genetic variants. Allele A is associated with dose of warfarin as compared to allele C. 27121899 1448109677
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *2 + *3 acenocoumarol dosage yes in South Indian Patients With Mechanical Heart Valves. Patients with wild type of CYP2C9 (*1/*1) required a mean daily dose of 2.70 mg as against 2.24 mg for all patients with CYP2C9 mutant genotypes considered together (P=0.008). CYP2C9 *2 + *3 are associated with decreased dose of acenocoumarol in people with Rheumatic Heart Disease as compared to CYP2C9 *1/*1. 27335128 1448255545
CYP2C9 CYP2C9*2, CYP2C9*3 *2 + *3 warfarin dosage not stated This study assessed the clinical application of genotype-guided dosing of warfarin. The algorithm used to guide dose of warfarin included these variants. CYP2C9 *2 + *3 are associated with dose of warfarin in people with Stroke. 25989350 1448276267
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 warfarin metabolism/PK yes The *1/*3 diplotype was associated with increased clearance of R-warfarin but decreased clearance of S-warfarin. CYP2C9 *1/*3 is associated with clearance of warfarin in people with Heart Diseases as compared to CYP2C9 *1/*1. 27763679 1448276214
CYP2C9 CYP2C9*3 *3 warfarin dosage not stated This study undertook warfarin prescribing based on CYP2C9*3 and VKORC1 rs9923231 genotype. CYP2C9 *3 is associated with dose of warfarin. 18183038 1448276332
CYP2C9 rs1799853 TT warfarin metabolism/PK yes The outcome of this study was the variable rate of fall in the INR in patients withdrawing from warfarin treatment prior to elective surgery. Patients were assessed along with rs1057910. Patients with two variant alleles *2*2 or *2*3 had increased odds of having an INR over 1.5 on the planned surgery. Genotype TT is associated with decreased clearance of warfarin as compared to genotypes CC + CT. 26010205 1448112390
CYP2C9 rs1057910 CC warfarin metabolism/PK yes The outcome of this study was the variable rate of fall in the INR in patients withdrawing from warfarin treatment prior to elective surgery. Patients were assessed along with rs1799853. Patients with two variant alleles *2*2 or *2*3 had increased odds of having an INR over 1.5 on the planned surgery. Genotype CC is associated with decreased clearance of warfarin as compared to genotypes AA + AC. 26010205 1448112396
CYP2C9 CYP2C9*2, CYP2C9*3 *2 + *3 warfarin dosage not stated These variants were included in an algorithm generated within this study, the WRAPID Dosing Algorithm. CYP2C9 *2 + *3 are associated with dose of warfarin. 21725053 1448276433
CYP2C9 CYP2C9*2, CYP2C9*3 *2 + *3 warfarin dosage not stated This study assessed whether a pharmacogenetic algorithm, which included these variants as well as the VKORC1 rs9923231 and CYP4F2*3 variants, is superior in overall anticoagulation control when compared to clinical standard of care. CYP2C9 *2 + *3 are associated with dose of warfarin. 26710337 1448276503
CYP2C9 rs1799853 CT clopidogrel efficacy no Response measured as platelet reactivity index using the vasodilator-stimulated phosphoprotein index and a cut-off value of >=60% was defined as hypo-responsiveness. Genotype CT is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to genotype CC. 25060201 1448258628
CYP2C9 rs1057910 AC clopidogrel efficacy no Response measured as platelet reactivity index using the vasodilator-stimulated phosphoprotein index and a cut-off value of >=60% was defined as hypo-responsiveness. Genotype AC is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to genotype AA. 25060201 1448258637
CYP2C9 rs9332092 TT warfarin dosage yes The mean warfarin dose was higher in patients with the TT genotype (3.5+/-2.0 mg/day) as compared to those with the CT genotype (2.5+/-1.0 mg.day). Genotype TT is associated with increased dose of warfarin as compared to genotype CT. 21326313 1448276066
CYP2C9 rs9332098 GG warfarin dosage yes The mean warfarin dose was higher in patients with the GG genotype (3.5+/-2.0 mg/day) as compared to those with the AG genotype (2.5+/-1.0 mg.day). Genotype GG is associated with increased dose of warfarin as compared to genotype AG. 21326313 1448276076
CYP2C9 rs9332238 G warfarin dosage yes The G allele was strongly associated with high warfarin dose (G allele, OR: 6.8 [5.0–9.1]; p = 4.4 × 10-13) in Brazilian patients. This variant is in virtually perfect LD with CYP2C9*2 (rs1799853) and CYP2C9*3 (rs1057910). Allele G is associated with increased dose of warfarin as compared to allele A. 26265036 1446534354
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *2 + *3 phenprocoumon dosage no in patients with ventricular assist device (VAD). CYP2C9 polymorphisms showed no effect on PC doses. CYP2C9 *2 + *3 are not associated with decreased dose of phenprocoumon as compared to CYP2C9 *1/*1. 26984978 1448255703
CYP2C9 CYP2C9*1, CYP2C9*3 *3 warfarin dosage yes CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 27488176 1448257202
CYP2C9 CYP2C9*1, CYP2C9*2 *2 warfarin dosage yes CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 27488176 1448257212
CYP2C9 CYP2C9*2, CYP2C9*3 *2 + *3 warfarin dosage not stated Generation of an algorithm to predict warfarin dose based on these variants as well as VKORC1 rs9923231 and clinical factors, as well as analyses on the performance of the algorithm vs a clinical algorithm. CYP2C9 *2 + *3 are associated with dose of warfarin. 18662264 1448267502
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *2 + *3 warfarin dosage yes in patients after aortic valve replacement within the 3 months of follow up. CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 27511999 1448257366
CYP2C9 CYP2C9*1, CYP2C9*13, CYP2C9*3 *1/*3 + *1/*13 zafirlukast metabolism/PK yes Higher Cmax and AUC, and lower CL/F of zafirlukast were observed in subjects with CYP2C9IM (*1/*3 and *1/*13) as compared to CYP2C9EM (*1/*1). The CL/F of zafirlukast was 42.8 % lower in the CYP2C9IM group compared with the CYP2C9EM group. CYP2C9 *1/*3 + *1/*13 are associated with decreased clearance of zafirlukast in healthy individuals as compared to CYP2C9 *1/*1. 27377818 1448123026
CYP2C9 CYP2C9*1, CYP2C9*13, CYP2C9*3 *1/*3 + *1/*13 zafirlukast metabolism/PK yes Higher Cmax and AUC, and lower CL/F of zafirlukast were observed in subjects with CYP2C9IM (*1/*3 and *1/*13) as compared to CYP2C9EM (*1/*1). Compared with the CYP2C9EM group, the Cmax and AUCinf of zafirlukast in the CYP2C9IM group were 1.44- and 1.70-fold higher. CYP2C9 *1/*3 + *1/*13 are associated with increased exposure to zafirlukast in healthy individuals as compared to CYP2C9 *1/*1. 27377818 1448123039
CYP2C9 rs1799853 C warfarin dosage not stated This variant annotation is part of a dosing algorithm table based on 8 genetic variants. Allele C is associated with dose of warfarin as compared to allele T. 27121899 1448109670
CYP2C9 rs9332131 A warfarin dosage not stated This variant annotation is part of a dosing algorithm table based on 8 genetic variants. Allele A is associated with dose of warfarin as compared to allele del. 27121899 1448109688
CYP2C9 rs28371685 C warfarin dosage not stated This variant annotation is part of a dosing algorithm table based on 8 genetic variants. Allele C is associated with dose of warfarin as compared to allele T. 27121899 1448109696
CYP2C9 rs72558189 A warfarin dosage not stated This variant annotation is part of a dosing algorithm table based on 8 genetic variants. Allele A is associated with dose of warfarin as compared to allele G. 27121899 1448109703
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 pioglitazone metabolism/PK yes CYP2C9*1/*3 showed a likely accelerated metabolism of pioglitazone. PCR-RFLP was done for *3 (A1075C in exon 7). Patients got single dose of 30 mg. From the 21 healthy subjects 19 were determined as CYP2C9*1/*1 and 2 as *1/*3. the mean AUC0–48 of pioglitazone in the two CYP2C9*1/*3 subjects was significantly lower to 50.78% of the CYP2C9*1/*1 (4849.40 ± 1626.91 vs. 9550.75 ± 3014.41 ng/ml× h, P<0.05). Cmax and Tmax in the CYP2C9*1/*3 subjects decreased to 60.22 and 76.69% of that of CYP2C9*1/*1 (652.50 ± 204.35 vs.1083.52 ± 372.92 ng/ml, and 1.25 ± 1.06 vs. 1.63 ± 0.85 h). CYP2C9 *1/*3 is associated with increased metabolism of pioglitazone as compared to CYP2C9 *1. 28099407 1448567530
CYP2C9 rs1057910 AC + CC warfarin dosage yes Genotypes AC + CC are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype AA. 28550460 1448624168
CYP2C9 rs1799853 T piroxicam efficacy not stated Subjects had at least one impacted lower third molar extracted. Measurements were taken of 1) postoperative mouth opening (millimeters) was measured pre- and post-op on days 2 & 7 2) and swelling measurements due to edema were recorded and 3) subjective measures of pain. None were associated with the genotype. Allele T is not associated with response to piroxicam as compared to allele C. 28740425 1448820078
CYP2C9 rs1799853 T piroxicam efficacy not stated Subjects had at least one impacted lower third molar extracted. Measurements were taken of 1) postoperative mouth opening (millimeters) was measured pre- and post-op on days 2 & 7 2) and swelling measurements due to edema were recorded and 3) subjective measures of pain. None were associated with the genotype. Allele T is not associated with response to piroxicam as compared to allele C. 28740425 1448820083
CYP2C9 CYP2C9 poor metabolizers endoxifen metabolism/PK yes An increase the steady-state endoxifen concentration was found for patients with increased CYP2C9 phenotype activity. After adjustment for CYP2D6 diplotype, weight, and season the association remained significant. Endoxifen concentration 2C9 PM: 6.26 ng/ml, 2C9 IM: 7.18 ng/ml, 2C9 NM: 8.29 ng/ml. CYP2C9 poor metabolizers are associated with decreased concentrations of endoxifen as compared to CYP2C9 normal metabolizers. 28877533 1448994296
CYP2C9 CYP2C9*1, CYP2C9*11, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*8 *2 + *3 + *5 + *8 + *11 warfarin dosage yes in African American patients. CYP2C9 star alleles were grouped together for analysis ( CYP2C9*2, *3, *5, *8, *11). CYP2C9 *2 + *3 + *5 + *8 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 28135054 1448573256
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 phenytoin toxicity yes Concentrations in *1/*3 were 3x more likely to have toxic concentrations of phenytoin compared to *1/*1. CYP2C9 *1/*3 is associated with increased concentrations of phenytoin in people with Epilepsy as compared to CYP2C9 *1/*1. 28302415 1448612922
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*2 + *1/*3 valproic acid dosage yes CYP2C9 *1/*2 + *1/*3 are associated with decreased dose of valproic acid in people with Bipolar Disorder and Psychotic Disorders as compared to CYP2C9 *1/*1. 27353638 1448428115
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*2 + *1/*3 valproic acid metabolism/PK no CYP2C9 *1/*2 + *1/*3 are not associated with concentrations of valproic acid in people with Bipolar Disorder and Psychotic Disorders as compared to CYP2C9 *1/*1. 27353638 1448428159
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *2 + *3 warfarin metabolism/PK yes Clearance of S-warfarin was reduced by 25, 39 and 47% among heterozygote for CYP2C9*2 (n = 41), CYP2C9*3 (n = 26) and carriers of 2 variant alleles (n = 14) as compared to CYP2C9*1/*1 carriers. CYP2C9 *2 + *3 are associated with decreased clearance of warfarin in healthy individuals as compared to CYP2C9 *1/*1. 27878474 1448568092
CYP2C9 rs1057910 AA warfarin dosage yes Genotype AA is associated with increased dose of warfarin in people with heart valve replacement as compared to genotype AC. 28429387 1448615546
CYP2C9 CYP2C9*1, CYP2C9*13, CYP2C9*3 *1/*3 + *1/*13 + *3/*3 celecoxib metabolism/PK yes Individuals with CYP2C9*3 and CYP2C9*13 variant alleles had increased plasma concentration (AUC) and decreased clearance of celecoxib. CYP2C9 *1/*3 + *1/*13 + *3/*3 are associated with decreased clearance of celecoxib in healthy individuals as compared to CYP2C9 *1/*1. 27864660 1448431851
CYP2C9 rs1057910 AC warfarin dosage yes Genotype AC is associated with decreased dose of warfarin as compared to genotype AA. 29054760 1449005162
CYP2C9 rs1057910 AC warfarin dosage yes Genotype AC is associated with decreased dose of warfarin as compared to genotype AA. 28262345 1449005213
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *2 + *3 warfarin dosage yes CYP2C9 and VKORC1 variants are analyzed together to divide patients into three warfarin sensitivity types (normal, sensitive and highly sensitive). "Warfarin sensitive and highly sensitive responders had heparin therapy discontinued earlier (p<0.001), had a decreased final weekly warfarin dose (p<0.001), spent more time over-anticoagulated (p<0.001) and had an increased bleeding risk with warfarin (sensitive responders HR 1.38 [95% CI 1.11 to 1.71], p=0.0035; highly sensitive responders 1.79 [1.09 to 2.99]; p=0.0252)." CYP2C9 *2 + *3 are associated with decreased dose of warfarin in people with venous thromboembolism as compared to CYP2C9 *1/*1. 28689179 1449005291
CYP2C9 rs9332131 del warfarin "dosage","efficacy" not stated Case report is of a 38-year-old African–American woman with pulmonary embolism and carrier of the rare CYP2C9*5 (rs28371686 G), CYP2C9*6 (rs9332131 del) alleles and required an average of 5.3 mg/day of warfarin during the dose initiation phase and decreased maintenance dose requirement of 2.5–3.6 mg/day. Despite JD’s VKORC1 rs9923231 GG genotype, indicating insensitivity, actual warfarin dose was 22–25% and 47–49% lower, respectively than if estimating a warfarin dose utilizing clinical factors only. Allele del is associated with decreased dose of warfarin in Pulmonary Embolism as compared to allele A. 28685643 1449005482
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *2 + *3 acenocoumarol dosage yes Acenocoumarol doses were 21.4% lower for carriers of the *2 or *3 variant as compared to those with the *1/*1 genotype. Additionally, the study also developed an algorithm to predict stable acenocoumarol dose that included this variant. CYP2C9 *2 + *3 are associated with decreased dose of acenocoumarol in people with Atrial Fibrillation and venous thromboembolism as compared to CYP2C9 *1/*1. 25089947 1448259384
CYP2C9 CYP2C9*1, CYP2C9*2 *2 acenocoumarol dosage yes Normalized maintenance dose (NMD): mean maintenance dose/INR at equilibrium). A final multivariate regression model explained 48.1% of the global inter-individual variability in dose requirement. The authors created a clinical algorithm (CA) using patient’s clinical and demographic variables used in the PA. CYP2C9 *2 is associated with decreased dose of acenocoumarol in people with Atrial Fibrillation as compared to CYP2C9 *1. 29479633 1449188252
CYP2C9 rs1057910 C warfarin dosage yes Dose was weekly dose corrected for weight in kg. Allele C is associated with decreased dose of warfarin in people with venous thromboembolism as compared to allele A. 29432897 1449190935
CYP2C9 CYP2C9 haplotype endoxifen metabolism/PK no CYP2C9 poor metabolizer and intermediate metabolizer genotypes are not associated with concentrations of endoxifen in women with Breast Neoplasms. 29436156 1449170856
CYP2C9 CYP2C9 haplotype 4-hydroxytamoxifen metabolism/PK no CYP2C9 poor metabolizer and intermediate metabolizer genotypes are associated with concentrations of 4-hydroxytamoxifen in women with Breast Neoplasms. 29436156 1449170881
CYP2C9 CYP2C9 haplotype n-desmethyltamoxifen metabolism/PK no CYP2C9 poor metabolizer and intermediate metabolizer genotypes are not associated with concentrations of n-desmethyltamoxifen in women with Breast Neoplasms. 29436156 1449170905
CYP2C9 CYP2C9 haplotype tamoxifen metabolism/PK no CYP2C9 poor metabolizer and intermediate metabolizer genotypes are not associated with concentrations of tamoxifen in women with Breast Neoplasms. 29436156 1449170929
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 celecoxib metabolism/PK yes The expression of CYP2C9*3 led to increased drug exposure (AUC) and slowed drug disposition in healthy Chinese male subjects. CYP2C9 *1/*3 is associated with decreased metabolism of celecoxib in healthy individuals as compared to CYP2C9 *1/*1. 26360837 1449171322
CYP2C9 CYP2C9*3 *3 warfarin dosage not stated used in a study comparing genotype-guided dosing vs conventional for warfarin initiation. CYP2C9 *3 is associated with dose of warfarin in people with Atrial Fibrillation, Pulmonary Embolism, Stroke and Venous Thrombosis. 29986700 1449577166
CYP2C9 CYP2C9*3 *3 warfarin dosage not stated as part of a model estimating mean daily warfarin requirements in milligrams per day. CYP2C9 *3 is associated with dose of warfarin. 17015052 1449577192
CYP2C9 rs1799853 CT warfarin dosage yes Genotype CT is associated with decreased dose of warfarin as compared to genotype CC. 28049362 1449192282
CYP2C9 rs1799853 T warfarin dosage no Although in the first analysis, the T allele was not found to be associated with warfarin dose in this population, the polymorphism was included in the International Warfarin Pharmacogenetic Consortium (IWPC), which was compared to a traditional clinical algorithm and the IWPC algorithm predicted dose better than the clinical algorithm. Allele T is associated with dose of warfarin in people with Cardiovascular Diseases as compared to allele C. 29568565 1449262882
CYP2C9 CYP2C9*3 *3 phenytoin "dosage","metabolism/PK" no Series of three case reports of patients with elevated phenytoin concentrations and designated as poor or very poor metabolizers of phenytoin following genetic testing. Two cases also presented with possible symptoms of phenytoin toxicity. Case 1 was heterozygous for CYP2C9*3 and CYP2C19*2, Case 2 was homozygous for CYP2C9*3 and Case 3 was heterozygous for CYP2C9*3. CYP2C9 *3 is associated with increased concentrations of phenytoin. 25597548 1449565307
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 phenytoin "dosage","metabolism/PK" no Case report of an infant patient with phenytoin toxicity as a result of elevated phenytoin levels. Genetic testing found that the patient had the CYP2C9 *1/*3 diplotype. CYP2C9 *1/*3 is associated with increased concentrations of phenytoin in children. 25998968 1449565369
CYP2C9 CYP2C9*2, CYP2C9*3 *2 + *3 methadone metabolism/PK no CYP2C9 *2 and *3 alleles did not influence (R)-, (S)- or (R,S)-methadone peak or trough plasma levels. CYP2C9 *2 + *3 are not associated with concentrations of methadone in people with Opioid-Related Disorders. 17178267 1449266467
CYP2C9 CYP2C9 poor metabolizer buprenorphine efficacy no Response defined by changes in the rate of dropout from treatment between metabolizer phenotypes. Study genotyped for the CYP2C9 *1, *2, *3, *4, *5 and *6 alleles and then assigned metabolizer phenotypes. CYP2C9 poor metabolizer is not associated with response to buprenorphine or methadone in people with Opioid-Related Disorders as compared to CYP2C9 intermediate metabolizer and normal metabolizer. 29333880 1449271199
CYP2C9 CYP2C9 extensive metabolizers warfarin dosage yes Mean dose (in mg) of warfarin according to metabolizer phenotype was: EM>IM>PM. Metabolizer phenotype was based on presence of CYP2C9*2 and *3. Warfarin dose requirement was defined as the reported daily dose at 3 months following treatment initiation. CYP2C9 normal metabolizers are associated with increased dose of warfarin as compared to CYP2C9 poor metabolizers and intermediate metabolizers. 29298995 1449164047
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *2 + *3 warfarin dosage yes CYP2C9*2 and/or *3 genotypes were characterized by lower estimated warfarin dose (median, 21 vs. 35 mg/week, p=0.02). CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 26469104 1447520031
CYP2C9 CYP2C9*2 *2/*2 voriconazole metabolism/PK not stated Case report. One Caucasian patient homozygous for the CYP2C9 *2 allele (i.e. a poor metabolizer) and homozygous for the CYP2C19 wild-type *1 allele. The apparent oral clearance, area under the concentration-time curve from zero hours to infinity (AUC0-inf), volume of distribution and half-life time were "not different" (though note that they were not identical) between the patient with the *2/*2 genotype and healthy volunteers from a previous study with the *1/*1 genotype. No statistical analyses were done. CYP2C9 *2/*2 is not associated with concentrations of voriconazole. 16940139 1446906191
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*3 + *2/*3 fluvastatin efficacy no Response determined as change in levels of LDL (WMD: 4.13; 95% CI: - 8.52 to 16.78; P = 0.522; with no evidence of heterogeneity), total cholesterol (WMD: 1.94; 95% CI: - 6.29 to 10.16; P = 0.644; with no evidence of heterogeneity), and triglycerides (WMD: - 1.88; 95% CI: - 25.96 to 22.21; P = 0.879; with no evidence of heterogeneity). CYP2C9 *1/*3 + *2/*3 are not associated with response to fluvastatin as compared to CYP2C9 *1/*1 + *1/*2. 30363031 1450361662
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*24 *2/*24 warfarin dosage not stated Case report of a patient with the *2/*24 genotype. The patient has lower warfarin dose requirements (1.5mg/day) than matched patients with the *1/*2 genotype. CYP2C9 *2/*24 is associated with decreased dose of warfarin in women with Cardiomyopathies as compared to CYP2C9 *1/*2. 16543980 1450814021
CYP2C9 CYP2C9*1, CYP2C9*3 *3 fluvastatin metabolism/PK yes This variant is in complete LD with rs77760615. This variant is significantly associated with increased area under the plasma concentration-time curve (AUC) of both 3R,5S-fluvastatin and 3S,5R-fluvastatin and total fluvastatin. CYP2C9 *3 is associated with increased concentrations of fluvastatin in healthy individuals as compared to CYP2C9 *1/*1. 30989645 1450823485
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *3 + *2 ibuprofen metabolism/PK not stated CYP2C9 *3 + *2 are associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1/*1. 19480553 1450935257
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*3 + *2/*3 + *3/*3 tolbutamide metabolism/PK yes CYP2C9 *1/*3 + *2/*3 + *3/*3 are associated with decreased clearance of tolbutamide in healthy individuals as compared to CYP2C9 *1/*1. 11875364 1450809160
CYP2C9 CYP2C9*3 *3/*3 acenocoumarol dosage no in an individual with additional genotypes VKORC1-1639A/A (rs9923231 AA) and VKORC1-1173T/T (rs9934438 TT). Patient was discharged with a prescription of an extremely low dosage of acenocoumarol (0.5 mg/day) combined with vitamin-K enriched diet and weekly INR monitoring. After a month of treatment, the most appropriate dosage that resulted in therapeutic anticoagulation levels (INR 2.5–3.5) was 0.5 mg of acenocoumarol every 3 days and time in therapeutic range during the following year was approximately 75%. CYP2C9 *3/*3 is associated with decreased dose of acenocoumarol. 30983536 1450415269
CYP2C9 rs149158426 T tolbutamide metabolism/PK no In vitro analysis showed that intrinsic clearance of tolbutamide by CYP2C9 protein containing the C allele was 98.1% of that of the WT protein. Variant referred to as 801C>T in the paper. Allele T is not associated with clearance of tolbutamide as compared to allele C. 30745309 1450935708
CYP2C9 rs762081829 T tolbutamide metabolism/PK yes In vitro analysis showed that intrinsic clearance of tolbutamide by CYP2C9 protein containing the T allele was 23% of that of the WT protein. Variant referred to as 218 C>T in the paper. Allele T is associated with decreased clearance of tolbutamide as compared to allele C. 30745309 1450935691
CYP2C9 rs202201137 G warfarin dosage no in a single individual who also had "factors like the advanced age of the patient, liver function, co-morbidities, drug-to-drug interactions and the presence of other polymorphisms (CYP2C9*2 and CYP2C9*5) " Allele G is associated with decreased dose of warfarin. 30518301 1450180271
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*2 + *2/*2 + *1/*3 + *2/*3 + *3/*3 tolbutamide efficacy no Plasma concentrations of insulin and glucose did not differ between genotype groups. CYP2C9 *1/*2 + *2/*2 + *1/*3 + *2/*3 + *3/*3 are not associated with response to tolbutamide in healthy individuals as compared to CYP2C9 *1/*1. 11875364 1450809573
CYP2C9 CYP2C9*1, CYP2C9*2 *1/*2 + *2/*2 tolbutamide metabolism/PK no CYP2C9 *1/*2 + *2/*2 are not associated with decreased clearance of tolbutamide in healthy individuals as compared to CYP2C9 *1/*1. 11875364 1450809558
CYP2C9 rs77760615 G fluvastatin metabolism/PK yes This variant is significantly associated with increased area under the plasma concentration-time curve (AUC) of both 3R,5S-fluvastatin and 3S,5R-fluvastatin and total fluvastatin. The AUC was 82% larger per copy of the variant allele. This variant is in complete LD with CYP2C9*3. Allele G is associated with increased concentrations of fluvastatin in healthy individuals as compared to allele A. 30989645 1450823480
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*24 *2/*24 warfarin dosage not stated Case report of a patient with the *2/*24 genotype. The patient has reduced clearance of S-warfarin than matched patients with the *1/*2 genotype. CYP2C9 *2/*24 is associated with decreased clearance of warfarin in women with Cardiomyopathies as compared to CYP2C9 *1/*2. 16543980 1450814028
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*3 + *2/*2 + *2/*3 + *3/*3 phenytoin dosage yes Low-intermediate/poor CYP2C9 genotype was associated with greater odds of having a lower dose by the end of the first year of treatment in the full cohort (OR 1.11; 95% CI: 1.02–1.22; P=0.02). CYP2C9 *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with decreased dose of phenytoin as compared to CYP2C9 *1/*1. 31461080 1450969293
CYP2C9 CYP2C9*1, CYP2C9*2 *1/*2 phenytoin metabolism/PK yes Compared to CYP2C9 extensive metabolizers (*1/*1 by the absence of *2 or *3), high-intermediate metabolizers (*1/*2) had an 8.6 pg/mL increase in mean dose-ad- justed phenytoin blood concentrations [95% confidence interval (CI): 2.3–14.8pg/mL; P<0.01] CYP2C9 *1/*2 is associated with increased concentrations of phenytoin as compared to CYP2C9 *1/*1. 31461080 1450969140
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *2 + *3 warfarin dosage yes Patients carrying at least one copy of the CYP2C9 *2 or *3 alleles needed significantly lower doses of warfarin and also showed significantly greater variability in dose as compared to patients with the wildtype *1/*1 genotype. CYP2C9 *2 + *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1. 22990331 1183689399
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *3 + *2 meloxicam metabolism/PK yes The population PK model predicted CL for meloxicam was decreased by 15%, 29%, 40%, 55%, and 80% in subjects with CYP2C9*1/*2, *2/*2, *1/*3, *2/*3, and *3/*3 genotypes, respectively, compared with that in subjects with the CYP2C9*1/*1 genotype. The effect of *2 on metabolism is moderate compared to *3. CYP2C9 *3 + *2 are associated with decreased metabolism of meloxicam in healthy individuals as compared to CYP2C9 *1/*1. 29024493 1451092660
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 + *3/*3 piroxicam metabolism/PK yes One subject with *3/*3 showed significantly higher AUC, reduced clearance and increased TxB2 and PGE2 AUC as compared to *1/*3 and *1 /*1 carriers. CYP2C9 *1/*3 + *3/*3 are associated with decreased metabolism of piroxicam in healthy individuals as compared to CYP2C9 *1/*1. 17112811 1451092520
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*3 + *2/*2 meloxicam metabolism/PK yes CYP2C9 *1/*3 + *2/*2 are associated with decreased metabolism of meloxicam in healthy individuals as compared to CYP2C9 *1/*1. 26774055 1451092564
CYP2C9 CYP2C9*1, CYP2C9*3 *1/*3 meloxicam metabolism/PK yes CYP2C9 *1/*3 is associated with decreased metabolism of meloxicam in healthy individuals as compared to CYP2C9 *1/*1. 24615047 1451092600
CYP2C9 CYP2C9*1, CYP2C9*13 *1/*13 meloxicam "PD","metabolism/PK" yes Individuals with *1/*13 had 2.43- and 1.46-fold higher AUC and Cmax than in the CYP2C9*1/*1 group. The oral clearance of meloxicam is 37.9% of wild type. The CYP2C9*1/*13 genotype is also associated with increased pharmacodynamic effects of meloxicam. Individuals with *1/*13 had greater inhibition of TXB2 generation ( lower rate of TXB(2) production) than in the CYP2C9*1/*1 group. CYP2C9 *1/*13 is associated with decreased metabolism of meloxicam in healthy individuals as compared to CYP2C9 *1/*1. 21395648 1451092671
CYP2C9 CYP2C9*1, CYP2C9*2 *2 ibuprofen metabolism/PK yes This was significant for the S enantiomer but not the R enantiomer after multivariate analysis and Bonferroni correction. CYP2C9 *2 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1/*1. 26122864 1447682551
CYP2C9 CYP2C9*1, CYP2C9*3 *3 ibuprofen metabolism/PK yes This was significant for the S enantiomer but not the R enantiomer after multivariate analysis and Bonferroni correction. CYP2C9 *3 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1/*1. 26122864 1447682561
CYP2C9 rs28371686 G warfarin dosage not stated using the extreme-discordant-phenotype (EDP) methodology. This variant defines CYP2C9*5. The EDP approach contrasts the most sensitive and the most resistant phenotype groups, which in the case of a quantitative trait such as the individual warfarin dose requirement correspond to the lower and upper ends of the dose distribution histogram. Allele G is associated with decreased dose of warfarin as compared to allele C. 19387626 982036951
CYP2C9 rs28371686 C warfarin dosage not stated This variant annotation is part of a dosing algorithm table based on 8 genetic variants. Allele C is associated with dose of warfarin as compared to allele G. 27121899 1448109681
CYP2C9 rs28371686 G warfarin "dosage","efficacy" not stated Case report is of a 38-year-old African–American woman with pulmonary embolism and carrier of the rare CYP2C9*5 (rs28371686 G), CYP2C9*6 (rs9332131 del) alleles and required an average of 5.3 mg/day of warfarin during the dose initiation phase and decreased maintenance dose requirement of 2.5–3.6 mg/day. Despite JD’s VKORC1 rs9923231 GG genotype, indicating insensitivity, actual warfarin dose was 22–25% and 47–49% lower, respectively than if estimating a warfarin dose utilizing clinical factors only. Allele G is associated with decreased dose of warfarin in Pulmonary Embolism as compared to allele C. 28685643 1449005488
CYP2C9 rs72558187 CT irbesartan metabolism/PK yes Subjects were healthy Korean males between the ages of 20-24. Each subject received a 150-mg oral dose of irbesartan after overnight fast. Subjects were maintained in the fasting state for 4 h after administration of the drug. Venous blood samples (10 mL) were obtained before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, and 36 h after irbesartan administration. The PK parameters of irbesartan were estimated using non-compartmental methods. In the study the rs72558187 C is referred to as the CYP2C9 *13 allele. Differences in PK parameters are in reference to CYP2C9 *1/*13 (rs72558187 CT) vs CYP2C9 *1/*1 (rs72558187 TT). Genotype CT is associated with decreased clearance of irbesartan in healthy individuals as compared to genotype TT. 21842338 1447947832
CYP2C9 rs72558187 CT irbesartan metabolism/PK yes Subjects were healthy Korean males between the ages of 20-24. Each subject received a 150-mg oral dose of irbesartan after overnight fast. Subjects were maintained in the fasting state for 4 h after administration of the drug. Venous blood samples (10 mL) were obtained before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, and 36 h after irbesartan administration. The PK parameters of irbesartan were estimated using non-compartmental methods. In the study the rs72558187 C is referred to as the CYP2C9 *13 allele. Differences in PK parameters are in reference to CYP2C9 *1/*13 (rs72558187 CT) vs CYP2C9 *1/*1 (rs725588187 TT). Genotype CT is associated with increased concentrations of irbesartan in healthy individuals as compared to genotype TT. 21842338 1447947839
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 warfarin dosage yes CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1. 31395958 1451120160
CYP2C9 rs1057910 AA warfarin dosage yes Patients had a stable therapeutic international normalized ration (INR) between 2 and 3. Genotype AA is associated with increased dose of warfarin as compared to genotypes AC + CC. 21383771 769182559
CYP2C9 rs1057910 AC phenytoin "other","metabolism/PK" not stated as measured by urinary (S)-p-HPPH. [stat_test: Kruskal Wallis]. One individual genotyped to be CYP2C9*2/*3 (rs1799853T and rs1057910C) had even lower (S)-p-HPPH and (R)-p-HPPH ratio. Genotype AC is associated with decreased metabolism of phenytoin in people with Epilepsy as compared to genotype AA. 16815679 769250031
CYP2C9 rs1057910 C warfarin dosage yes This SNP defines CYP2C9*3. CYP2C9 *2,*3,*4,*5,*8 were grouped into three groups for testing: *1/*1 vs. *1/*2 + *1/*3 + *1/*4 + *1/*5 + *1/*8 vs *2/*2 + *2/*3 + *3/*3 + *5/*5. People having one or two variant alleles had lower dose requirements than people who were *1/*1. Allele C is associated with decreased dose of warfarin as compared to allele A. 21228733 827864562
CYP2C9 rs1057910 C warfarin "dosage","efficacy","toxicity" not stated Reduced function alleles CYP2C9*2 and CYP2C9*3 are pooled together for analysis. "Patients in the low-dose group were more likely to have difficulties at the time of induction of warfarin therapy (5.97 [2.26-15.82]) and have increased risk of major bleeding complications (rate ratio 3.68 [1.43-9.50]) when compared with randomly selected clinic controls." Allele C is associated with decreased dose of warfarin as compared to allele A. 10073515 982033269
CYP2C9 rs1057910 C warfarin dosage yes in Turkish patients taking warfarin for >2 months. This variant defines CYP2C9*3. Homozygous variant genotype (*2/*2,*2/*3,and *3/*3) are grouped together, and heterozygous variant genotype (*1/*2,*1/*3,and *1/*4) are grouped together for analysis. Patients carrying one or two copies of CYP2C9 variant alleles are associated with lower dose of warfarin as compared to the homozygous wild type patients. Allele C is associated with decreased dose of warfarin as compared to allele A. 18542936 982036698
CYP2C9 rs1057910 C warfarin dosage yes C (*3) was associated with 38.1 %(95% CI 29.3 -45.7%) reduction in therapeutic dose (defined as the dose that gave an INR in the target therapeutic range after 7 consecutive days) per copy. Allele C is associated with decreased dose of warfarin in people with total knee or hip arthroplasty as compared to allele A. 17387222 1183699320
CYP2C9 rs1057910 AC irbesartan metabolism/PK yes Subjects were healthy Korean males between the ages of 20-24. Each subject received a 150-mg oral dose of irbesartan after overnight fast. Subjects were maintained in the fasting state for 4 h after administration of the drug. Venous blood samples (10 mL) were obtained before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, and 36 h after irbesartan administration. The PK parameters of irbesartan were estimated using non-compartmental methods. In the study the rs1057910 is referred to as the CYP2C9 *3 allele. Differences in PK parameters are in reference to CYP2C9 *1/*3 (rs1057910 AC) vs CYP2C9 *1/*1 (rs1057910 AA). Genotype AC is associated with decreased metabolism of irbesartan in healthy individuals as compared to genotype AA. 21842338 1447947817
CYP2C9 rs1057910 AC irbesartan metabolism/PK yes Subjects were healthy Korean males between the ages of 20-24. Each subject received a 150-mg oral dose of irbesartan after overnight fast. Subjects were maintained in the fasting state for 4 h after administration of the drug. Venous blood samples (10 mL) were obtained before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, and 36 h after irbesartan administration. The PK parameters of irbesartan were estimated using non-compartmental methods. In the study the rs1057910 is referred to as the CYP2C9 *3 allele. Differences in PK parameters are in reference to CYP2C9 *1/*3 (rs1057910 AC) vs CYP2C9 *1/*1 (rs1057910 AA). Genotype AC is associated with decreased clearance of irbesartan in healthy individuals as compared to genotype AA. 21842338 1447947794
CYP2C9 rs1057910 AA warfarin dosage yes 158/220 patients had the target INR (1.5–2.5). The comparison of weekly warfarin maintenance dose was among patients of different genotypes. The mean maintenance dose per week was significantly lower in the rs1057910 AC genotype (15.31±5.26 mg/w) vs the AA genotype (21.21±6.98 mg/w, p = 0.002 ANOVA). rs9923231 and rs1057910 had significant effects on maintenance dose (rs9923231: coefficient was 1.398, p < 0.001; rs1057910: coefficient was-0.994, p < 0.001) and together explained apx. 32.0% of warfarin maintenance dose variability. Genotype AA is associated with increased dose of warfarin in people with heart valve replacement as compared to genotype AC. 25594941 1444694693
CYP2C9 rs1057910 AA warfarin metabolism/PK no 130 plasma samples were obtained 12 hours after the last dose of warfarin. The plasma warfarin concentrations of these samples were comparing plasma concentration within a group of patients with INR between 1.5–2.5 (n = 92) between genotype groups. The relationship between plasma concentration and maintenance dose was evaluated to explore the effect of rs1057910 (CYP2C9) on the pharmacokinetics of warfarin. Within both the low-dosage group (<17.5 mg/w) and the middle-dosage group (17.5–26.25 mg/w) the AC genotypes required higher plasma concentration as compared to the AA genotypes although the differences were not statistically significant. Genotype AA is not associated with concentrations of warfarin in people with heart valve replacement as compared to genotype AC. 25594941 1444694702
CYP2C9 rs1057910 AC irbesartan metabolism/PK yes Subjects were healthy Korean males between the ages of 20-24. Each subject received a 150-mg oral dose of irbesartan after overnight fast. Subjects were maintained in the fasting state for 4 h after administration of the drug. Venous blood samples (10 mL) were obtained before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, and 36 h after irbesartan administration. The PK parameters of irbesartan were estimated using non-compartmental methods. In the study the rs1057910 is referred to as the CYP2C9 *3 allele. Differences in PK parameters are in reference to CYP2C9 *1/*3 (rs1057910 AC) vs CYP2C9 *1/*1 (rs1057910 AA). Genotype AC is associated with increased concentrations of irbesartan in healthy individuals as compared to genotype AA. 21842338 1447947806
CYP2C9 rs1057910 AC irbesartan metabolism/PK yes The study was conducted in individuals from Anhui province in China (Dongzhi and Taihu counties) with essential hypertension (systolic blood pressure (SBP) between 140-200 mmHg and diastolic blood pressure (DBP) between 90-115 mmHg age 35-60). Individuals took 150 mg/day irbesartan for 28 days. Blood samples were taken 24 hours post dose on the 27th day [Log C24h] and 6 hours post-dose on the 28th day of the study [Log C6h]. The AC genotype (N= 79) was associated with increased concentrations of irbesartan as compared to the AA genotype (N= 1008). Genotype AC is associated with increased concentrations of irbesartan in people with Essential hypertension as compared to genotype AA. 16094537 1447947867
CYP2C9 rs1057910 AC irbesartan efficacy no The study was conducted in individuals from Anhui province in China (Dongzhi and Taihu counties) with essential hypertension (systolic blood pressure (SBP) between 140-200 mmHg and diastolic blood pressure (DBP) between 90-115 mmHg age 35-60). Individuals took 150 mg/day irbesartan for 28 days. At the end of the study blood pressure was taken 6 hours post-dose and 24 hours post-dose. There were no significant changed in SBP or DBP between genotypes in individuals taking irbesartan. Genotype AC is not associated with response to irbesartan in people with Essential hypertension as compared to genotype AA. 16094537 1447947879
CYP2C9 rs1057910 C piroxicam efficacy not stated Subjects had at least one impacted lower third molar extracted. Measurements were taken of 1) postoperative mouth opening (millimeters) was measured pre- and post-op on days 2 & 7 2) and swelling measurements due to edema were recorded and 3) subjective measures of pain. None were associated with the genotype. Allele C is not associated with response to piroxicam as compared to allele A. 28740425 1448820088
CYP2C9 rs1799853 CT irbesartan efficacy yes Subjects were part of the Swedish Irbesartan Left Ventricular Hypertrophy Investigation (SILVHIA). This study analyzed data for subjects who were either randomized to 50 mg/day atenolol (N= 53) or 150 mg/day irbesartan (N=49) over 12 weeks. If diastolic blood pressure (DBP) remained greater than 90 mmHg at 6 weeks doses were doubled. At 12 weeks 67% of patients treated with irbesatran had to receive a 300 mg dose. By the end of the study, mean dose diastolic blood pressure (DBP) and systolic blood pressure (SBP) were assessed between the CYP2C9 *1/*2 (rs1799853 CT) genotype as compared to the CYP2C9 *1/*1 (rs1799853 CC) genotype. At the end of 12 weeks there was a significant decrease in DBP in those with the CT genotype as compared to the CC genotype but no significant difference in SBP. There were insufficient numbers of subjects with the *3 allele (rs1057910 C) (*1/*3, *2/*3, *3/*3) and so it was not analyzed. Genotype CT is associated with increased response to irbesartan in people with Hypertension as compared to genotype CC. 12359989 1447947908
CYP2C9 rs1799853 CT atenolol efficacy no Subjects were part of the Swedish Irbesartan Left Ventricular Hypertrophy Investigation (SILVHIA). This study analyzed data for subjects who were either randomized to 50 mg/day atenolol (N= 53) or 150 mg/day irbesartan (N=49) over 12 weeks. If diastolic blood pressure (DBP) remained greater than 90 mmHg at 6 weeks doses were doubled. At 12 weeks 42% of patients treated with atenolol had to receive a 100 mg dose. By the end of the study, mean dose diastolic blood pressure (DBP) and systolic blood pressure (SBP) were assessed between the CYP2C9 *1/*2 (rs1799853 CT) genotype as compared to the CYP2C9 *1/*1 (rs1799853 CC) genotype. At the end of 12 weeks there was a significant decrease in DBP in those with the CT genotype as compared to the CC genotype but no significant difference in SBP. There were insufficient numbers of subjects with the *3 allele (rs1057910 C) (*1/*3, *2/*3, *3/*3) and so it was not analyzed. Atenolol was not associated with a significant change in SBP or DBP when comparing between genotype groups. Genotype CT is not associated with response to atenolol in people with Hypertension as compared to genotype CC. 12359989 1447947949
CYP2C9 rs1934969 AT + TT losartan metabolism/PK yes Subjects carrying the T allele showed significantly increased losartan metabolic ratios (losartan:E-3174) as compared to subjects homozygous for the wildtype genotype (AA). This association was only seen in the Swedish cohort, but not in the Korean cohort. Genotypes AT + TT are associated with decreased metabolism of losartan in healthy individuals as compared to genotype AA. 22294058 1183697248